var title_f5_43_5808="Contents: Pulmonary infections";
var content_f5_43_5808=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?15/21/15710\">",
"       Infectious Diseases",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pulmonary infections",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pulmonary infections",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Atypical pneumonia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/19/38199\">",
"           Clinical manifestations and diagnosis of Legionella infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/58/32680\">",
"           Epidemiology and pathogenesis of Legionella infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/5/3162\">",
"           Mycoplasma pneumoniae infection in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/6/7270\">",
"           Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/14/8425\">",
"           Psittacosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/15/33015\">",
"           Treatment and prevention of Legionella infection",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bronchitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/38/29289\">",
"           Acute bronchitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/43/7866\">",
"           Management of infection in acute exacerbations of chronic obstructive pulmonary disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Community-acquired pneumonia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/33/29210\">",
"           Antibiotic studies for the treatment of community-acquired pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/36/38473\">",
"           Community-acquired pneumonia in adults: Risk stratification and the decision to admit",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/26/26026\">",
"           Diagnostic approach to community-acquired pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/49/31514\">",
"           Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/38/23143\">",
"           Microbiology and pathogenesis of Streptococcus pneumoniae",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/24/23945\">",
"           Nonresolving pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/4/13386\">",
"           Pneumococcal pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/12/21705\">",
"           Pneumococcal vaccination in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/48/1801\">",
"           Prognosis of community-acquired pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/5/81\">",
"           Resistance of Streptococcus pneumoniae to beta-lactam antibiotics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/18/3369\">",
"           Resistance of Streptococcus pneumoniae to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/15/19704\">",
"           Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/24/24969\">",
"           Treatment of community-acquired pneumonia in adults in the outpatient setting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/1/40986\">",
"           Treatment of community-acquired pneumonia in adults who require hospitalization",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fungal infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/5/38998\">",
"           Amphotericin B nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/26/1449\">",
"           Diagnosis and treatment of histoplasmosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/23/21881\">",
"           Diagnosis and treatment of pulmonary histoplasmosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/63/39924\">",
"           Epidemiology and clinical manifestations of histoplasmosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/51/34616\">",
"           Epidemiology and clinical manifestations of invasive aspergillosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/51/39734\">",
"           Management of pulmonary sequelae and complications of coccidioidomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/24/42376\">",
"           Pathogenesis and clinical features of pulmonary histoplasmosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/10/12458\">",
"           Clinical manifestations and diagnosis of bronchiectasis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/7/17524\">",
"           Clinical microbiology review: Respiratory tract infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/9/24729\">",
"           Lung abscess",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/24/23945\">",
"           Nonresolving pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/27/28089\">",
"           Parapneumonic effusion and empyema in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/48/1800\">",
"           Postoperative mediastinitis after cardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/5/37978\">",
"           Pulmonary complications of primary immunodeficiencies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/43/14005\">",
"           Renal disease in tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/11/17591\">",
"           Sputum cultures for the evaluation of bacterial pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/11/38073\">",
"           Treatment of bronchiectasis in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         HIV infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/43/20154\">",
"           Approach to the HIV-infected patient with pulmonary symptoms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/5/15449\">",
"           Bacterial pulmonary infections in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/25/7577\">",
"           Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/41/19093\">",
"           Cytomegalovirus infection as a cause of pulmonary disease in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/46/12009\">",
"           Diagnosis of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/63/39924\">",
"           Epidemiology and clinical manifestations of histoplasmosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/10/1194\">",
"           Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/29/36310\">",
"           Parasitic pulmonary infections in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/52/2889\">",
"           Prophylaxis against Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/60/27593\">",
"           Treatment of Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/12/4298\">",
"           Treatment of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/47/22261\">",
"           Tuberculous pleural effusions in HIV-infected patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Influenza",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/60/39880\">",
"           Antiviral drug resistance among seasonal influenza viruses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/31/35320\">",
"           Avian influenza vaccines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/4/22599\">",
"           Clinical manifestations and diagnosis of avian influenza",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/27/37305\">",
"           Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/1/18456\">",
"           Clinical manifestations of seasonal influenza in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/25/5528\">",
"           Diagnosis of seasonal influenza in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/58/15272\">",
"           Epidemiology of influenza",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/2/31786\">",
"           Epidemiology of pandemic H1N1 influenza ('swine influenza')",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/48/14090\">",
"           Epidemiology, transmission, and pathogenesis of avian influenza",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/34/2599\">",
"           Infection control measures to prevent seasonal influenza in healthcare settings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/11/19640\">",
"           Pharmacology of antiviral drugs for influenza",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/13/44249\">",
"           Prevention of seasonal influenza in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/8/37002\">",
"           Seasonal influenza vaccination in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/7/39032\">",
"           Treatment and prevention of avian influenza",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/21/38234\">",
"           Treatment and prevention of pandemic H1N1 influenza ('swine influenza')",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/46/22250\">",
"           Treatment of seasonal influenza in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nosocomial pneumonia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/18/31017\">",
"           Aspiration pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/30/24040\">",
"           Clinical presentation and diagnosis of ventilator-associated pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/32/27145\">",
"           Epidemiology and pathogenesis of Pseudomonas aeruginosa infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/57/12183\">",
"           Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/48/31494\">",
"           Pseudomonas aeruginosa pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/7/13433\">",
"           Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/34/6695\">",
"           The ventilator circuit and ventilator-associated pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/63/36858\">",
"           Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other respiratory viruses",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/38/617\">",
"           Parainfluenza viruses in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Parasitic infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/24/36229\">",
"           Cutaneous larva migrans (creeping eruption)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/38/15977\">",
"           Epidemiology, pathogenesis, and clinical features of schistosomiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/28/42437\">",
"           Hookworm infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/29/36310\">",
"           Parasitic pulmonary infections in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/25/11668\">",
"           Pulmonary manifestations of ascariasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/34/16935\">",
"           Toxocariasis: visceral and ocular larva migrans",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/54/15207\">",
"           Trichinellosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/30/2532\">",
"           Tropical filarial pulmonary eosinophilia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pneumocystis jiroveci (P. carinii)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/25/7577\">",
"           Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/8/22665\">",
"           Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/52/2889\">",
"           Prophylaxis against Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/4/9289\">",
"           Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/60/27593\">",
"           Treatment of Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Severe acute respiratory syndrome (SARS)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/21/17753\">",
"           Severe acute respiratory syndrome (SARS)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tuberculosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/47/39673\">",
"           Clinical manifestations and evaluation of pulmonary tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/46/12009\">",
"           Diagnosis of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/13/18649\">",
"           Epidemiology of tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/10/1194\">",
"           Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/12/4298\">",
"           Treatment of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Viral infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/41/19093\">",
"           Cytomegalovirus infection as a cause of pulmonary disease in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/56/7050\">",
"           Respiratory syncytial virus infection: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/17/15640\">",
"           Respiratory syncytial virus infection: Prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/27/38327\">",
"           Respiratory syncytial virus infection: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/21/17753\">",
"           Severe acute respiratory syndrome (SARS)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-5B6EC77130-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f5_43_5808=[""].join("\n");
var outline_f5_43_5808=null;
var title_f5_43_5809="Fusarium skin lesions on lower extremities";
var content_f5_43_5809=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fusarium skin lesions on lower extremities",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 315px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE7AaQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD10iijIpM1jc0sLSg0zNLuouOw8mkpu6gmncVgNNozSilcdhMU9VoFSLSuVYTbRtp9LSuFiMilxTqQ07isNooyKAadxWFxSEU7NBouFhlFKTTc0XCw8GnhqhzS5oHYsb6TOahDc04NRcLDjSEUZpCaLgIRTaUmmk0XFYWimZo3Ci4WH0UzcKNw9aLhYU00015VXqyj8arSXtsgy9xCo93AouKxaBpax5df0yIEvfQcejZqvJ4r0ePreofoCaOZD5WdBmgmuQufH+jQ5CvLIR/dSs64+JFmP9Tayt/vECjmQ+Vnf5pQ1eWXHxLmb/j2s0X3ck1Qn+IWqyfc8mMf7K5pcyDkZ7GTTGcAZJAFeG3HjLWZm5vGUeijFZlzrV/O3726mbP+2RRzor2TPe5tRtIc+bcwrj1cVmXXizR7dtr30ZP+zzXhjXUu45cnPqc1E7Z5Ocnqan2hSonsF3490qPOwyyY6bVxmsi5+IkWD9ns2Ldt7V5oBx1/Cgk5zxU+0K9kjt7j4gX7/wCqhhQeuM1mz+MdWkzsuPL/AN1RXN8seKQg8jNLnZXs0aM+u6jOGEt3M2f9uqUlxK/VmJ7kk1EEwc0p3dM8elLnZXs0Jvb1P1pNxJwTmnckYxUYBZuOMUudlKHkOG7tjH1opVBXggflRVqWhm6ep28PxF1lDl0tpP8AgGKuxfEq9A/e2UJz6MRXGG3YCkaAD72eaz9qx+zR3kPxLkBxNpyn/ckq9F8SLMgGWznX/dINeaCLa3Qn6VIIlfg8Gn7Vi9kj1GH4h6Q/3hcR/VM/1q2njnRGx/pLD6oa8gaEA470nkZ7fkKftWL2R7RH4v0RxkX8Y+oP+FWIvE+jyfd1G3/FsV4b5DZG39aPIJ5zwKPah7Fnvaa5phPGoWuf+ugqzFq1g5AW9tjn/poK+fJEJzyeeKYFAOPmHsDR7UPZM+j1vbVulzCf+BipBPERxLGfowr5uw2cAkf5+tBklTgSPz/tH/Gn7QPZs+kTPF/z0T/voUxriLP+tTP+8K+cGaYkYlfHsxpVMxHLtkf7Rp+0QeyPoo3UI/5axj/gQpGu4F6zxD6sK+dnEuM72/76P+NNYSuxyzkduTS9qL2LPon7fagZNxDj/fFJ/aVoBzdQf9/BXzrtfOCWz7//AK6kCNgZY0e0H7Fn0A+s6coJN9bAD/poKgbxBpSg5v7fj/bFeChCxPPHuKUxgAZ70e0F7JnuU3inR4l3NqEBH+y2f5VWbxpoi/8AL6p9gprxJUyxADUphPTJJPvR7QfsT2RvH2iL/wAtpSPURmq0/wAR9JjH7tLiQ+gXFeRMrBsYxjtQqhjhh+VHOP2R6rJ8TLIKdlnOT7kVWf4mr/BYt+LV5n5eCcZFOMWQOaXtA9kehS/E6b+CwQfVjVWX4lX7n93awIPfJrhxAe/SkCYYjFHtBezR15+IersxAEA/4BVKbx1rbuW+0hB6KgrAVOKTyt3K8Gj2g/ZmrL4p1mfO++m/Diqkms6kRhr64I/3zVFlK8nkUqr0pcw/ZkrajeOfnuZTn1c1E9w7t80jkfUmniIN0/lTGgwef0o5h8iImGTnJo3MRgn6cVJ5DE4HApjIQDkcDvS5h8g0fKeTS+xojG7tUyIQ3TNHMPkIWXHSkKnHarBAOfWkRd3U8HpxS5h8hCq96GwTwOasCMg43UwxkHOfyouHKQ7PmGeKk8sKOMmnxDORtY9smngYJGKVykiDbk88U4IAfWrAibgkDFLsBHGaVwsVH+U9D+Ap0cYYbuauKgGO5p5i3JwQPalcdiiFwfapWt+AQetTiAg1IYjtyT+Ao5h8pQ8g7ck4bpjFKsJzuOPpVvZv4AcY7mpEgAAO0Z9SaVx8pXZBnp+lFXhEWGSKK1jsYS3H+WA3TNSGIHGfSpUByQVNDMQNoXPrmsLmtirKnzDHT27VFtBm25BNXyp9h7U0Rgszd/wp3DlKxjQHPU0eXntgVbFu56cCnCAB/mbIFFwsUhFkkDrTGtyoyDV2MISwAYN/OpCiqB8vFFwKLIQuCFqDysgkDnpWk6FmG0DFCwZXpx+VFwsZqxNu4INI8S5O48+3atAQ/P8AeAFOARW2sCfcCncLGf5KhRg5pCqjHqa0WCqmdpP4VGsY4IX86LisUljBPIoaLHIfAFXPLG75l5pzopUgLRcdiksYdf8AGkaD5cg5PpUrI4fKoRxipoo/lyzHn2ouVYoGN9uMdfalWJiMEH61orGSBzwKVcK21j1ouTYzfKIPU/lRGgByQc1oGJd+Q1I1vk5P6UXCxSli+bIU5qF7duDnFaTQ7hgEgetHlbFAxu96LhYz44DkfNn61LJGoXjFXQqKMsP0pr+WB9wcmi4WKP2d8ZQA0GFh8xANXVG8/ISMdqcI3K470XFYoBGJBIGKc0bhBtAz6Va8kgknml8sjnOKLj5SkI2YgOoA+lMMEu4gKPatHYSRhwcc0pRjxuA96LhYpxWzAc4z9aTycn5vzq4QSSo6jr70oiZuSwHtRcdjPZWBxjj1pjRZ4JGDWg6beGPNMa2DYJXmi4+UoiDHbv1FBjwTV2QeUowmaTaHj5XaOuPWi4WKYh24brmgQEsBk1NOrAAcCiDe+c9qdxEZiAwoVs0ghKZJbHtVyOFt2Tu/wp0kODkDJ9TSuFmUyrcFDgdMU9IztJ61YQS/xqNtO9VKlQe4pXK5So6jA3BjUoBCBsYHTFWPL2EcPn1qZIST8xJz6ii4WKaITzjHvVhYRgZwRU4UZwpWnhC38WcelAcpWeEtwBwKYVEQyUJq7GhEmF3EVM2AAHz+VIZRCgpuYYHXFNliBALH5R6Vohgy4259MimLGSw+UD1oGZ+xjjAIFFbBXOPlHSito7HPLcgjDLik8kEkjqalKuCAee9ShGPSuc0Kmza3IH40KmAfl61dKFTyvOO9IqliMfr0oKuV0V1PoKfsBJ4OetTLHiT5iMU5Qd2MEHPFAimqFs4UDnvT2J2ldo/KrLKTncoz6Uu3KgD6UXAppH8ucFR6U/ySwI+8uKtMrB+eo7U7a7L93rRcdjNMGM7VNOKMq5AGPpVxISFIU856ZqMrIGK84/SncLFZYWx0/CniNznggY9KsJ9wnOMcE013VlwHJHqDTCxRlVt/FDRsVO3AJFXgqrGW4P1pqKMfMRg9KNSLlaOF1X94FPH5VHEu4/Sr7BMgYO3uKjMQRRsBGKCkyv5TEkgjjtiowm5sOPmqw/mFwAMCnCIjBPXPSgCIxKrD5sCmvB/ECce1WxAj8kEkUu0JwA2PSkBTWPcnBqMblbHar7RbuB8opY4gexwOMU7lGeQ2eRxTZASPu8Cr8kZ3kAYo8sshBHSgVjKDAtgKRVtYiFBUnP1p4tW3ZqZoX4GAMdT60XEVGgZpRlsU4xjac5OPpUzZwNozzSop5ynGeaCinuUtgAj3xUqxFZFy2R16VdEceOV/IdKZLGjA/MwOOOKLjSRWcKWHqfQVGQCeFOB3pyB1kGCCvfNWlI25VFP+NFxuJSMann9aURAgsW57A1YYqOXABzUTTJJkkNkcfdoAiZDtA3DrQYnAyQMDmpljBUN2pxTsX+U9qAsVvIEnD4x1pi2yoxIbg1bSDbyPm/HpUgXA+ZRnsKBWKTIOhbH403btk2mTPFaAiQDey7c9e9MZI2fKr2x0oGV3JVeBj3o8tpEzuBH8qcbaQsSxLJ2FT2VkzmU+ZHBHFG0skkzhUjRVLMzH0ABoWuiBpJXK8MfP32J7A1aO1Rz1Ap01tLBcskpjJIVlaNgyspAKsCOCCCCD70rwo7BmOCKLWE0Qsm4/ID7YxTTFiQDLqe/FWUCquY+oqQGRlwR17mgCpFHhiEcg0ucHoxx1zU6bVbDDaT3qTyhjcDk+9AEELCUcLjBpzrMRhMA9qnjQgcbcGnoHLrkADPWkNFHMq8SH5vairkoy5yORxRWkdkYS3ZLNAMjse1NVDuIY9BnirSqcnJBHvS7eThcDHpWJZXVMrnA49aSVdnRevWp1+9jGCaUgMAWBJB5xTHYiRRsyVAHTJphAMmBkgeg6VYIOcdj3p0UR2ZHr2oEQG3LDeGOB1psqOI8I+PbHWrMiuc4yBnuKjZCSDmgARe55OKSRH8wAH5T+lEaMZTljVsowXIIAxQBTRAoPyknPJpzhUjJwG9qtQqC+G5qKUYnXaOD1NBRRKqAeMA84zWBqfibStL1B7W8d4pQAQUXK4PrXV3K+ZEeBkD0xXhfxHJ/4SeYHqEUfpW9GmpuxjWqOCuelR+KtDnAH25N3bdxVuLXNNZljivIGJ6fOK8G8tgqswIDdCeM1e07Tbi+hvJIMbbWPzZMntkDj8xW/1aPc5vrMux7s93ADlSrepVgRQLhZOFx7814zJoGrQTiJY2LmcWwCt/GRkD8qatlrMSpIpmw8TzKwfqiEhj17EGl9WXcf1nyPZk+YEybSvbBpXUN8quV+nNeP7PEUexc3a72VV+Y8ll3KPxHNMGqa9EoYz3QBUsCT2BwT+dL6t5j+so9mgG1CrPk+ppHcoeuTXkP9u+IkAUzXPULgr3IyB+VH/CS6+gz50uME529h1p/V5d0P6yux6+z+YByAcdKN4iAGa8jHijXkYgu5IOCDH3pP+Ev1vrvHc58sUvq8vIPrET1pZRMc/Nkd8UShirBXAz0ryceMNcA4cdcf6v1po8Wa11G0nBbPl9hwTR9Xl5D+sQPXooyAPmLE0r8pz06E15C3i7XsEAlegOIsdelNXxP4g/hd/wCI/c/u9fyqfq0u6D6xA9fihQJlcA/Wp4U3huRXiLeNNcOf9MbB9AK9M+Ht5PfaEk95I0rs7DJHQVM6Dpq5pCspysjoXOGEYJx1yBTZAScJgY65qyikt8y/L2pHQtIwAAAxWB0IpPD8mNvzHqaalsxIJf5ewq6sflgg85OabvGz5oypHegpsomAlzzkCkKhGwOKvCJOi7ue9DW67vlILe9AiuihFJbB3dMdaGVXIwf0q08asDuTGe49qhMI3LjgCgCN4yY+NuOmaZ5ZyAwOR/EKsmNR8oLFuvA6U+7uLK1utHsriGVBqatFDqDTDyluwxxbOuPl3JtKuWwS2MYBIqMXJ2RE5qCuyqU42kfL6mljQAZjI/HpVu3tkNytrc3At5pWeKJJFOZJQjOI8didhFV4wRnCjYRzSs0UmnoCW7XLJGkqIzsF3Nwq5PUn0qKaDzNE8VxedFMbfS9QjnEUgYxOlvKdrY+6dy9Dg1PhWUq2ATXlPxx0mS11K08SWLNGt/GbS8MZK/vlQAk+0kZGfUh62oRUpehhiZuENNmeqb7YWHhf7TPDBc6jp2nJEHY5lke2hGFUZZvmOOAcd8UlzEYrmWOMJMqMV3jOGweoryT4E6e914muNbuS0i6XAEgLnP791KRjn+6gkcenlivZwCB0BY0V4qMrLqLDzlNXey0KMXylN8R2jrjtUxaLdjDMOvNSM7O4zhB0qQmzt7Iy30phMs0dpbDGfNuHyUT8QrfpWKV3ZHRJqKuyDaCoLKB6DFSALgcVDfXNppOnSanrDvFZRsI0WMbpbiU/diiX+Jj+QHJ97lwgUx7Q8LNEjvDKQXhYqC0bEcblJKn3HbpTcWo83QnnjzcvUrhVAIClfc00xojKrH5uvBqQk7hlx9KhVA0hdj0qSyYRBiSCSM96KcgODj+ftRWkdkYS3ZZUnGCAOc4Pek+bcSEIx71JEA0m1iRnkE04qEyVyT3rnNbjBiRgQMdiP60sioMBePU+tSIwG4suCR+dC7cErg8cA1QFaVgvyjk0+OVVj5wD2qzKitErMAGz/DUfkx7M5z9aAIlkWSTaOPfPWieELghutSw2yqS6nj605whAL9KYXKUcDZLZ4qwAWQAYHaplVVGEBz6HpToYmCsdgzQBVMbJKFJGKeEwoJHHPNSGN9298Y6VL5fmRsg4UdKBMpzxebEcsQAM14L8Rht8UTD/AGF/lX0IbdYkIDE5GCK8K+I2nX114luLhLZgm1VwMdhiuvDNJ6nNiE2tC1ofxBgsLfTYrnRoLkWds9ttchkfLBt5Uj73bPpWgdWstfg8Varpunw6akemxKYFxgsJk5Ax7V5w9hdIPmt5Rj/ZNNVZo1YASKGGCBkAj3rs0OJpo6ceOL976K5mt7WRkvjqG3btBk2hccdsCtXw/rUWpWd5Fdm3tfsWkXEMRLH96zOWA+vJFeflT3GKXaTRyp7CudqnjjM1tJLYKfJnhlOHPPlReWB+PWm2WoQ3+kXahDFJa6bIjFn++WmDfL74OK4wggcV2PgSBLnTfEUc02nx7rIiMXLqrtJkEbM9+DRawiaTxfaNfQzray4ju4LkgkchIwpH5ip9O1G21LS7iOMCJrLS5g28j52abdxnqcHFcCQQSPQ9qMlehI+h60WA9Bi8TaOdSnmYSKjalb3C5jB/dohDfris+K5t77SrgW6szW1hL5pK4OTMCD+RArjRnFeifDTR/tthe3Vzp63FgHSK4fzWDsp6oiAjLZwcnIGKOWwzNTxBpq3VwWSUxyXttMDtGdkYw1WdIuINTg1BbYPug0+6kYsAOr5GPwri9QRI764SNHRFkYKr9VGehqGOR487HZdw2nacZHoarlEdhe+I7BppzFHMVa5tpRwM7Y1ww/GnafqUWom4jt0aNlS9nJJ4w65A/SuLJzmum8C2gub+QyR2zwoAH82RFIB4+UMwB/OjlGcuQc4PWvavhY2fDES7gF8xgc/WvKfE8Frb+IL+HT2RrRJSIihyNtep/ClGfw9GewkbisMR8BvhvjO6kiMkfbPsahjhKMuG3EnkDtVsB0AyoZfSogUEuI2PqRXnM9FB5K7gWbr0B702WEpkKoPcgnOB7VaMcbIGfJC88mmJFhSytnIOT7elA0yuI2GMjHpUZljAKspEn4VPJG4PLEqOQR2qS4sLm3KfbLaeIyLvQtGV3D156igCkXwiA556YoRVyT/F1qVbaTzjsPy+4pxg3ksThhx9aQ7FeLcSQMge9ZPjjVtA0Gxn0nxiZja6jAGMEELO7DqksT48vepOR83ByDwSK3mR9iMpzkEUkkCXlhNp+qW8F9YSHLW1wm5CcY3Durc/eUhh2Na05KMrszqxco2ifO9/8RNXv/EPhzU72Xz20OSN4n2bWnKOD5knJy7Kqg887fUkn6GlgjW5uUhIa3EjLGWP30B+Vh7EYP415R4v+DwfzLnwfcbyOW066kAf/tnIcBv91sHoAXNeh+GFuLvwpoz6lDNbX0NuLS5ilQo8ckH7oKwPIOxEY/71dNe0ocyOPDc0anLLqS3EIMwAkCnqFFRaxoMfiLw9faG+DJeJm2ZzgJOvMZz25yhPZZGq9JDjB439Oe3vTUgRuWZi2eCprkjNwldHdUipx5Wc/wDDnQJPD/gqwguFMF7cMb25R1IZS+BGh+iKrD03tXSTQOo+R+TzkVZunkuppJ7q4aS5kO5mb+I/41FboxBjLHGehFOpPnlzEU4ezjyleNd+N3O7nJ7Yryf49666azpehWcrJ/ZifapWRuRcSYYcj+7GI/oS3vXttlbyyOc2slwLdXmeGAZd1RSxUY7nGB7kV4uvwz1PW9Yu9X8X36Q3N5M9xLa2O2aUsxJIL5ESDnHDMR/d4xW+GSinORz4qTk1COpqeDfG+meINVGq+JdShg1+IeTYQSJ5NrZx8ZaI5KiRjklmII7c4K+hywywMEdPLO0EKVxgdjWT4a8O6T4bijk0jSba1u1P/H1M32m49iHZQEPvGq1q3Mss0zPIzSO3LOxJJ+pNRXnGTsjWhTlCN5f8EglQuwDMQfanCMiIgc0qrsj+bJ5zT8oV4Y+31rnN7jSgyc5X2oqVcDO9jnNFbR2MJbl7yxGu5xuDeh6UiyInyrkMfWnR7SnBK47GoWQiUjrnvXOaFiAAqWHPqG/pS5Vyo2hcUkEfyEA574zT4yBLzwB1phdiLHvQjdtZW606SPdHgMM9zwM0CNUViTlSck+lJGVCYYlhz2pgSxwEgGMAgDJNNY5Q7uRn0oTPIwCP97GKlhRsF1YAA9D3pARjljs4FKjhvl+br1pY0LSkkHPoOKsYwcMAV9KaArIuCVKkjsaLnKnaAcnH4VNah5Q+cgZ4FSKoVCMbjnqaAIApWPI5Iqp9jiuN/nRo2TySOlX0b98cbSuRQZFXap3HbnGB1pp2G0Zf9iadI2Htoz77aguPDmlBMyWsZ54word34ZsbQRzg9KY0iMoBUb+/pVJtdSGm+hzkvhTSJwxFnF+QrPl8EaO83NihXHUNXZ7Y0APG7+VNVS7MNw5HGBQpvuHIuxxEvgLQQT/opHr8x4qGb4daC6K3lzID1w//ANau5CBpHD9+MetPES45+/0GOcCq9rMXsodjzpfhposyEoblTxk7+Oar3Xwv06M7VmueeM16IyEkRsvOPvdOc1ZmL5UeYpIOQTVKtPuJ0I9jyd/hha78C7mHHdRUf/CuFjU+VfzgdQAO9etXEKS/LJknuRUa2gUhlPyg9M0e2mT7KPY8g/4VtG+CbuUMT3UVK/wuUHC3zHjj5K9WuI1ULtRgcHNIY0KqRvDjtT9vMfsYHlH/AAq4qD5l2w44IWlPwxWPBN6xznkL0Feo3av0O4ccU+K23ohdcj1o9tMPYx7Hl9r8LonbMt1IF/3a7rwroMOg2H2aOVpV3FhkVtRX9lPrGraOguYr7TVjlKzBcXEDgbZ48fw5OCD0yM9SBIlrNI/mIjERruIIxtGcZP4kUVJTfuyJpqL1iQSSmL7y4Hr6VKsdtJJceVdQy3NqUjuYozloGddyh/qPTPQjqDT5LeVw7Ab1RSz4GQq9yfQVx3ifxFouga/p3iEalYTRXMQ0rWLW3uY3mkhxmG4WMNkmMrtJx91VHc0qdPnui6s/ZpNHUNhlZkztDBGYA4ye314NPVFKcbc478VxHwt8YSeKrrxWZAILON7R7SBuTGoMy9e7NvBJ78AcAAd9FCshXcMkCoqQ5HZl06imuZELW9xGiOyHbIMqSuAfpWZom43vjSAMxK+Jrm4AB6+fHG367enasv4u2N+3hcar4furi11XR1MjG3dlMtqTl1IH3ghO/B4wZK8AfxT4m1y5urMajcSS6vNEJ44Qsf2iQL5aBtoGeDjHQ9Tk8100qSlB2e5y1a3LNabH1I1ufssEqyRtHMCyNHIG4DFT0/2lYY9jSJHtjGehOM0tvaW9hpthZWLiS2sYI7aORQQriMBS+P8AaILf8CNN1e/07RtGW+1a7FvC9wtuX8tiqFlJUsRnAO1hkjAxyea5nH3uWJ1qfuqUh7yWcd1/Zpmc6gLD+09gj+TyPP8AIzuz97f2x05z2pYuVchht6E9wKxDqmnD4hfav7RsTaf8Ibjz/tCeX/yFM/fzjpz1rT0rUtN1fSm1DSrj7RB9oa23LGwVyqgsVJxkDcoyBg54PFXUp2SaXQzp1U2031IzGqysyMVJ6tU0k93NbRQS3DvFFkxq3O3OMjPXHA46elOmClQApOe2KktYQBmVNuOh5rFN7G7stWVpYz5YVgCRVGaXy5NmDluwHSrt8xeR1EgUDp24rLuiyISvb1NBcI33JEnyxDEt6ZqxBcAPkgEfWsV7gqR5eWbuOAR+FIsriU7nHTpmkU4I6EXIbKB8KeoxnNMkbeFG7kf5+lZMDZJJIFXYj5hBYZHY0tbWM/Z8ruSuHYD5lbPGOlVnUq64OB35q5LCxXKgtjpiqs3zN8q4I600A4sWXaOlCoygYXINTwKCyqqFyeAoHJP9asyJLazvDPG0Uq/eRxgrkZ5FMV9SmDHk78g59KKtZR/mePnp+lFaRasZyi77DpMqeWUgjj6VJAPm65zUQjHA7HoetKHMTDC/KfTrXOWXY4gCdnDYzj1psyZ9AR1pkcgOGLHB4GOtLkyMGZfb60gJlj3ADbwR8xprQSbcKAD1HvT4pJVk2bcNjj0pzSMiqd4UnPynkVYDYwEQyFR9aVSrk4YADqM0CRnUcYI61B5pLYUDcep4GKBlp8iQYPyY7etPVyVAwx+uBVFJJFm2k5weRVicjKkIfMA5INFxWJIiTIAGIA/Sl80PIwbIOMZFEaHaGbgnvTkjETnrjqWqhWGQxYDBWIGcYOOtJcR4I54HcU9k3Nlm+XuV61HcxmWQeWxWMDo3rSGhOo5Xg9qR1UFWjPPoKFixGN5HIODmiKNYnYrIWPUA0wJJPLdAwfJ6EY6Uny+btiB2r145zTBGkykqhVwck9qWBjCwUbTjqe5oBIklSPAcg7unBoVOrBgGXkY9aS6fylUgcMc4A5zUUD+aPmHGeRQFrjpWCJ0zIefrT1JZQTtyR93b1pi3Ja6KlV+UYGe1V55XIyxwVPagQ+QP5IWNTkNkH1qaM/Lz8p4zxUMs4JXaWXHr3p8Mj793b0ouNolQ71G4ZApqbQ+5VJzwM9qNuHDEHDdOae25T8gJUelMkhuIXZw8hDLjpS28WUEZwsY5696mh8ySP51PFI7vAQYeCDuznpRcL9DnvGVpLFp9rr+nMsWtaHvmtpJyFjuoMHzrVyeqsCxA9SQOWzXIad8ULfXvipoOn6M08OhTrJE6SD5nnmhZVDeoR2UD1O49xjX+I3w90rxvJNqMU503X2HM5y0E5/6aKMlT/tL+KkkmvBLzStb+H/i3T5dVs5LW7tJ47uFshklCMGDI44YZHUH2rupKM4rW559bmhLax9T2SvE4uIXZhIuc4yrKR3B6gg8g15X8S/hEl75ureC7cJPy0+lJ0Y9SYP8A43/3zn7o9aWONSIopCsMUjxwyL0ZAcKfxAp7SENhJAuOQR1H4d65ozdKdjqlTVaF+p4D+z0GfxDrlo2UY2CyAYOQy3EIP0+Vnr3+MNEgLfNg8Edaq2uiaRP4jm1x4vs2tNbyQyTRfdudwBBkXu2QPn6+ueCtlWkV2V0JjA5PTNOvNTaaChCUE4yLSsiyh2VWUjDIy5BXHII7ggkEe9eKeEfh4dD+NsykN/ZOmwtqtpKTklGO2EZ7skjAH1MTdua9i3Mq7lcKOwAz+dKbxWs3tmRB86sX2gMcdFz1xk5x0yKVKtyJodSh7RpkMmYY0EZzGANiqOR2wao65ZW2u+HdQ0W4XbDfRGESNwsb5DJIT2CuFJ9gRVmR3Q/KGYH1FMlUoN7J8h4KdQayjK0uY2lBOPKfH39n3f8Aan9nfZ5Pt3nfZ/Ix83mbtu3HrnivrfQtOh0XQ9N0eEKbWwh8jep4kkyTJID6NIWI9iK55/AmPigPGOMWJt/ODEf8v+Nn/fWP3+f73tXUMCPkUhU2jav93HGK6sTUTikjkwtKXM20WoWj6bRznBB5qWZnEeM5GOPas+KExXEbbsp+lS3RMsZKOdwPQVxo7ZIzLlncMhj3Z71j3sRWSNi2EJ5Bbp+Fbs0cuSCGVx0NZDWzNKHdN788H+Kg3iVJpIR8zQsxzxIh+b8qjjkhkd1eR8EcZXB/GrJkME22DLE9UZeV+lJOFdlCREOerGmAkeFG3epGOCav6aSjAZ3DHfpVaNlX93t3DHJxV+yUL0PHoRUilsX41JbYm5iDhQP4iawPE/i7QPDBePWL7fernNjagSzA+jDIWP33ncOu0101pdS2cvnW0rRMVIOO4I5HuPauO17wD4X11HlfShZXHJM2nMLfJ94yDGR7Kqn3ral7O/7zc46vtWv3ex51d/E3VPEerWmlWV1H4a0a4mWKadJf3wiZvmaSbAOACchQqn0NerT+JfCUOQPFGjRqeEVGkcKB0HyocAdOa8zf4Taxpt/b6n4XvbPVfs0qzJbXSrbykqc4KMTGwOOgck+le2veXtokTG0fT3mjWUwPAInTIztYYGSM4zyPTiuir7Oy7eRzUVVTa6+ZUYxwsUM0b8KwZTwysoZSPqCD+NFTm6a4dpbh2eZzuZnIJY46k0Vy6PZHppO2pXjYjbgn1zUqt5jbsH5Qc1XBOF3A7R2BqQDupIx2rEgs4wiOmCe49KFlA7moNpbBWQDPvSDJTkfMKQWLInGQMk+tTTMsgAh+RB265NUsgAHNPikxx174qgsWXBGNr45HSovkYncDk8ZpxfdHtCgE9D6VC7BVBk3Aj0pAi1GF3tvJOMYNWRIu58Ku0VmG4jiX5+/XmmLdYYeWwweoz1qhODNaQb1VYduw89e9OkQqnzuTnGMVVilCQhsgseoFORy643gH3pisWGBMJVBhl6nNNVQyfNtBHc0xbZi+wndgdQetPi2wTLu/eLmhDFKowVFK7gMj3pinPHJOcYxSDaWZN2wnJFSIAFVlOT04piGknaFV9h7UCIk7wQfUf1poQJKWj4brhu9OVgrknKjuB3NAEc5cuMPle4pYyEY7Qcd801ADMX5K5qSRlU7+CxHUdqLDI72VEZSykH+LjrVaa4UyOV4XGMHqKL5WnXl8AEcHg/Ws+RZHyEX5z8ufX2oKjEkF9IXCuG8vsSOtaH2hC5CggYGMnqazbWzSSB3ebEsZxsJ6VDG375U3HeDgN7VNynE3onZgpIGBwc5yKdBcFWYHO31NU4rsoojfG7PD1Fq+uaNpP2O31zVrbT5byMzQCaOXY6hmT/WKpQHKngkcYPcVpGLlojCbjHWRsM+xd6klOfpVSadJThWAPTHY1yXxB8YX3hTRNK1jRbix1LSzeeRPDHOk0E4dCRlkJ2sPL4PBGT1BIOn4U8TaT4otDeaLI3loqme3lwZbZicYcd1PQOODwODxWjoyUb2MlWg5cp0IjygdQucYwKrahY2WraVJp2t2cN9ZM24wTnO0/wB5GHzI3uMflxUkigyAo2F9ziq89ygcMgzt6j+tZJuDvE2cFNWaLMqWtpb2sViZvJhgjiHnENJlEVMkgAHO3JPHJPAqrAJAXkckk9OKdI/nxhlXJ9PSrNu8ccaqzKQetDd3cIpQVkMVWZ3dCcAYOasBpDwyAEU5fLG47shhnFQyz/KSCeThaQXCSONZQXbg++MVDcqHwwQ46EetEkYmTHUjsT3qsXkVXBfO0gUgVyU/IgYqynoAT0pftAZAvPuPemedvjCSKHz3z0pJZlVEwgOeMnsKCyaVZY4hG7kxEkgnoPf8qqNE6Sl0JkQcHAqZJMFkdwy4474o8/zJVXouOccUDWhXaUs2wqUx0qS2bc371Mk8bs4pCd05Voxt7MOtKYXjGCTsJ4PpSB6omuI0aMn5vm4GT0rJu7ZsDAbK/dZTitOafIZNo5x+NLJEfKUK3ynqPT6UxKXKc+wkbbnAcccjB/OozCwfBU7ietbU9sBy2Sw5zUUkRIyTxjpQP2hQggKrkk+9X4okYBhnIFJEkb84O8d6lHyxnOAfTNFgcrg0oA2MR7c0iAYPOPaoSfMBVFVSOpqQJ8uARuyOaQk7EnlGNN6klKfO29hyWwuFGc4pFJVdjtgVGSY5MAgr6igE7sVVRhkrzx/Kimy/fzuxwO1Fax2RrzLuKqBcjOTijIUMSc56e1MLOGwcYxyKkRlC9BvP6VgZgGLLhBhTySR0ND7g5BOemMUjH5z2PQgdKR2MYGMFfWkBIVwSG5H8qZHkq2OD61CLglvlUE98mrMJCnJ70DJFAEZfJ3DtUUrEcluB1GKViAxIJ96iYFjuzw1WIqXswVApQFjzVWNmEucLn0rVmtQ0fIDH1FUTFhV3AGRPlPbig0jJWsXYbgAoCo2dSavwFM7l4z61j24J3I4AY8g+lasKn5VAwf50zOStsW1do8s+Sp4APFK8mBkMVBHpVW5dZFVAzAjjnj8qYgYR4O489zRcEhYtpkCjJfPU1d+eLaqBvfFQQiPcpCnI6nNTxu4LMcBR05zQS2hyuBHvYfOvrUJdiWUcq3erTyAbmXlTjdkUyMRlEbHyg4HvmmJSEVcBQFHJ7miaJSmGC59qZFE4lcu3Tpn+VWJpNqAFf/r0IGzNvCvlsx5fouOlUILl1lSR+qknIHX3/CtueGOZNrqEyMgisa9t2WUhFJGOnp70mawkhlw6C4JRslx371VklYuu1cEfxDv7UwlzIodcBaVMmVFUjHv2oNLGjAFYKSSc1qxXMyxfZAQ9u/3oHAdH+qnIP5VkxkWyAhSWPU+tTpcMm14yVlyCrLkEe4NVF2OaaUmeN/FPw7e+INfWHwj4JuEhtNy3F9Y6c8cU7nr90CMKuCAQBk56jFZPhj4d+O9N1KDUdNFvplzCTtlfUIAw7EFAxYgjIIKkEZB9K9u1PxHpumWscviG7uIFnuVt1umy6Rkqx/eDlgDt+8M49O4u3GIZIgXibzVEkTIwZWQ9GVhwQfUcV2e3cYp2OL6spSa5tSSyE82gwPq02npqx+WWGyMhjYAcMCyLtJ/ugkDsf4RUC7fuv1PINXJGDJH6jr61nzqxkBQZPpmuSclJ3R3U4KCs2aFioyWClcfxE0kibJSwcNk9xVMXDqoUqQPanN5hCyB2Kk4I44qRPcsi4ZACcMw4zTUkVZCPOOW5wRxmoFmYjD8NngY61DIxcls7T24oBItuybDl9ue1V1kKxdGIPfvUckwb5pFXJGM54qOGQyYbeCg4APUf/WpFpF3f+68wJvJGOOg9zSuw8sEyMp7bRkVnb0gYAFsKMlgf6VL9oCAmPAJHWTnH5UF2Ll1IIVwHVmI+8gqojFpCEOB39zUb3ASIKjr5h9RwPWmNKxbOF68kcUgsadvKfIKOqjn72asoytgRnKjqc1jNLhmVOARgAmrlpII2AcKBjjB60EOJeeKOV8dDio1fy3dGGV7U5XV23cA/WkPl3EfX5weCKDO9tyPzw0pBztxio3MaNk9PrTSnlP8AxGkTy5TzuJP4Ux2GMCx+TjvToLW4vlk8qMt5Sl3I6KB1Jqnrusad4b0k3+rXAgtySEwN0szD+GJf4j6kkKO56A+a+HviR/wkPjyK41i9t9B8P2cU0kNsSzIGZCm59oLSyYc84/3QoreGHlJXZhPERg+U9Xijb0GPXtT/ACj1yuKr6Rqun687/wBlW2tyWnlNIdSbTjDY5VSQod2DFmxgfL1I98W0Vdm8Dp2Jzz61lOm4fEaQqKp8JDMjS4YYGOMZ61FE7F1VwBzzUuQ7nkAUyEfvQH6CpNYkxkJ4CKQO9FAjC5w+AenBorWOyMZLVlZ3JwX6+vtTCG6jGO1K7DGDnNNXcrqCegzXMdBKjnd8x47U2Q7h257UrcfNkfSoy5LcYGPagY1TyNuADxmr0eABjGTxmq0cSE/N07VLkbSuBgdKYmTz4TIXgnrioUQ7lGeKjkfls84HSmxMS2VJ+lUBcjwgZSxz1BFQNGrnJXHqTTyZNwbIHbFKWY/KxGRzQSS2kUW5vMGMDip+UwTjg9BxxVJZxE4VjnnNSTXRBICgjGcmmJpsS6AluFZAQO4JqQE7D37D2qFZty7sACmySc/K2AaB+RYtmI/1fUnmrsK4BZzjB6GsmGRlZdjqxHp61eublZLaRQNsnGO2aBMkQgu2Gbceo7Usbqh4zk9jVK1k8wAs/wA3Tk9qbBOu9tuCQcfMen0pcw+U1nyhIb7hwSaSVQcFGbb3qvFOxLNwUHByaUsTzkqvancizLY27MdQB0PJ+tVLhWZ9nATrUkbDeG+YMOw6GonnBJABDetMmKdypcRCQsDgF+nFVobJo5WbgjtWk7pjDY64FRXEhiXC/MMdu1BXM9hqurEKy9uDio9QjmubW1js9d1fRXh3gtaCOWGXJzmSFxhyOgO7pxTVmGxd5AIqqZQ5ByxUHnFEZuLuhOkpKzPOvjde6vaeGLXTtW1PQ9US6nEkckdi1pdrsB+Yoh8oL8xHHPPHeuC8B+P7/wALlLS4j/tDRi25rR22tET1aJ8HYx78FT3BwMe5az4Z8MavrMmoahpFxfzkABLu9cpGo6Koj8vgfjkkk5JNWNP0rSLAj7Do2k2+0ghhZRswx0AdlLj867VXglZnHLDVG7r8y54f1Cx8R6N/aehXJurMELMSu2WBuyyL/CfoSp7E4OFMhilBb7p6Y6mppr+fyFSS7naJRtCPIxA9gM4xVFT5oBBBweK5KjUpXidtKMlH3y9KwYhlz7iomkEeURgG6880SMNpAypPGRVGQlZQT82RxjrUoe5ZLMyBn/Oqs0jNL5eF470ss+3aFz9DUUobeCpUluaCkKCCWWZCeOMGoJJBbRMCwKZ4PpTrmTaF5wv071majcI+eV6cY/rSNEEt9Eu5tzFyMZ7U6C8jYo6ytjI8w+p9q5m4u9ofLKrDvjqPSsk6vKgdd4Kt97GK0jG4pS5Tuo9Q82V0CxhCxwxPJ5rShcsIiOY84Ge59TXn2nai7Tgq4Cg9cdq6KLUy/lAAbsAFsnoB19KTgNM3pmbzUGeM55HNW1n3rgZ49ulZdvdmdSSygkcbqnhbbGTwzZ7GoaGblvdR9CfmAwRirAjCsdgwOvWuftZQZdx5OCSM+la9rciQDcpBpGc4Fi4YY27sn2NN064tbe5klu1dgQdm3n5uxIyCR3IBBPqOtRSxhJd3r1qlPhpdnQdc0J21IS59GcJ4w+Gt54j1N9Qn8XG8uXGB9rsDAkYHRFWN3CqOcADHtzWLofwz8W+H9as9X0C80S+ubSUOm258oN1BBEyx8EcduvavXoSuBgEgU8OGmUEYXrgmun63O2xzPCQvoy/dz3s8EE+rLJHcTR7yjzrMyHupdSQeR1HUYPeqOfIPByCKLhSG4GRUaEhSG9e9c8nd3OiKsrEjKMB1PB9KSJGPUEtmoGPktuydp7CpQ7MQyE4pGhK3mk/KwwKKhR354PWit47GTepXLhuh5FSRoG3B+uOtQDAZc4xjNShgU46Hr7VymwpweGOQOlJuIXkZHQUm7KnpxxTWJ47LQMTzRuCNkE+lToxOBnIFUpMl8t90dKljbcMg4x3NMLE07jeVPU9adGpVgysT6Cq1yUEuT94jrTomKzDDcUB0LcUp3HeM45xT0Xc+Q2AfxqjJMplKgkP60sUpj+8cDOcUElyZF3YbGR3qCaQDleaZ5m8Fu5qNyCwx19BVgizGpxvzhetMdgrhu+Me1RGV8EDoKhkcOoUHk0Atyysv8SLtXvx1p007ScyYwBjOay47gDK5YKv3Qf1pDJlcluR0pM0Ubmk9wEAWHBPqab55kkG1QOOayTNhf3bEZPOaRboiE7CWYcVJVjaS6ePAHC55q7HdBhxncBn61zqXRcAuc+1WLeeTfnGBQJxub8U7SK28le3FR7GVyc59GJqvFMGKhyOe1SyOSw5+X+VWc9uVjLpsyKQcNTfPLYiz83XNFzt8vdjBHc1RgGOec+tBcbMuSbF56tUUsyxgblGD6U8qrDrhu5qJmUt+GKAHoxWPeMk9etOSXzV+UfN71Ahw20Dg9qFl28GM896YMluF8wDcRn0FVoVMcjE5wO1EjksCuTn0ofcWBDc+p7UFLaxcDiRRlhnt7VBvyzBjtY/pVdkZXDKTjqae3z5J7cZoM7WIWGybDEMppPMdWUMFx29qMhRgkH3p0cpcYKjbnAPpQMZdAuNrY2Y4NYOpSbQEXAA5+tblyfLXux9qyr+FGRW5LdxiguByOoOZSVbIB9OM1xV/5kM7FS6oTxnoa9A1C2yHKDK+p7VmqkAEkN3brKHIO5v4PpXRSmo7mdem57GVpNwWiVk3bsY56Vu6fI8YJJJHYE1nxRRxOVRflHTHatGxjb5WxlTU1JJvQuEWlZ7nUaa6+W3y5UYOD61oC4Hm+WihRjnFZWn/AChR3YjNXEOdzgYbp6ZrBmhcDMNxIUAHGR1NaMG4MpBIXFZscksqsGC9OKuacjrksQaQp7Gs0gYYPIqtIpVsk4GcjNKW+YAtx9KhuQ29XRypXkEHkGgxhuWdQkj0qz+16tdWun2bDKTXMmwMO+wcs59lBPtXnOvfFzS7F3TQrN9VmAws12pht1PqIwd7/Usnutdr4l0PRfFx87xJZme92BBfQP5dxgDAy2CrdvvKx4wCK8w174N6jGrz+GL2HVYhz9nkxBcj2Ck7X9PlbJ/ujpXbRhRsu/mcNaVa77eR6x4Qn8R6v4RsbrWmlna7zeLHFEFjiRgAiqqDH3QDnr8xya0J4J7ZlS7ieLeu5AwxketcN4K0Dw/P4es01rwfZxanbZtrxbpZ45RKuOWXeOqlG6YyT6V2ISCC2trSwtoLOztUKQ28OdqAsWPUk5LMxySTzWVflu7bm2Hc+VbWJSoYYbpUVsGj3DqM8UsMnyleM0RH5juOKwOlEwdct9fSik37SQV/ziitY7IwluzGLtnipI5S3semKgAOTn0pVGD8vNc51F0ncCVGDUbSEZUnnFRbyp+U/WmOw35IoEPdieOM9alRw4CtyPaqu7OSfShCE9eaBvYs3R4HGcdKhjLAtnJBpXx5XUnvUSvx/FzxVEosEK7g546UjyAPtxke9R8BD83NMQkjkjdmgZbDgRbuMDtVZ3LShkJ+lJhmBAY4PqKR1KEYamBaSXIKnhgKruWLNjHHSkJyAepIqCWRkTjqaZMdxZJcuflxgVWlnDHb0xTLibKjHXvVZ2wu4AZpG6JriQCMbDjNMguAv3h0rMnmOA3QdDzUb3HG0HBo5R3Ns3OW3gYI/Wp7a8LtzkHtWJbuwBy2cVo2bj0qWgN+1YOwY8MO9XEck/K2ax4pFVAxbArSt+EUKeTTMJonuDvTaxqmimMjcxKnj6UkxkL5YkdsUqKXO3t3pkx0JCy7SqtketJYxJJdxrNOIo2YAuwJCe5xUPliMnnjNRSz2mn2cmoarfJZ6ejiPeyl3kcgkJGg5djj6DuR1qoxbdkVJqKu2ZHiLx94c8P3ktldW+vSXsfVDaxxIw7FXMjZB7Hbg1ylx8WrZ5QuneHbiV2bAF3fB9xzwAscaH8Mmuk8daNeeJvDVxLd2kOg2NjDLeWltdIJtSuisZb95yBAhx9zqeOH4Nc38H/CTQWi+KL1Qs7ErpSOOjA4a4/4DyE/28n+DnvjGnCN2jzJTqzlyp7/ACPSBcTnT7S1vLGxtNTTL3f2TzNqOekWXdj8n8XP3iR0UEscOgwx4NJGpi2qOQPzJpzyOeJV+ntXFVam7pHoUouEOV7jkBYrhyPakdiH2MOO5pIG2y8crVqQxOvzj5u1ZlTKLKBwveo1LxkgglRVhtqt/Ks9r1ftphOR7+tMSLTyDqWP0Iqper/q9pGB+tEzjzlBJ2nrTnRSAcgntQWjGvrclDgcGsqW0J3EjFdLJGSCG4AqrNDGW28474oTNOZHPfYmJBxj1q/aWvl429uRWmluN2F5HpTkgdWOBgdabYCwMysoCDA5yfWp95OAeW9xwKRd+4AAdemKvJGqEMyZNSxc1hmnJMXYT49vpWrGpVhjAHt3qCJ9wBC49qlmkcBdoAFIxlK4653cEHFRbt2FJwe5pZnDRgk8D0qCR13beRx3psIlxHCrg9PX1p6MM5RiV7iqkRGzYeT2p8SeUTzgHmgouyahdXMKWs87yW6HMcbtnZ9PSomPkkl+h6CoIgDKPlIx1NSTtvXBHTpSFawuGEoPJUjipGO4Ajgg1Xhkdl2Hr60/7y4U4YHk0Ay2khbJwDzRWeUbcxD7cnOKK3jsjGUXfYqPIDg/hiiJxu71DLw/QYNAOOnNcx0E7ng0xyWxSBsjpTGc9qoBSD0zT0bJwxxgVEW45OTQOMHPWgTZaJBGd3A7VUVzvboBUhkwOAKgkxwT1NMSJg5654FI/wA7ZD4qFGAGKUsB0oGWEfaN2ScU0Plieue1VnkC/KO9SBgsXyjLYpgTlzswPWqrS/eB7UsRIXJ61HIPmPpRYSepWkY7ifWqU8rYIA4FWpXC9BVeXBX3osapmdcNxn9KpF2JzmrlyhPU1FHDuPK1SAntHYlcnrW1aOFXnp6VkQQlGU54rSh6AVLQ7mlG4wM4I7e1acUoZcZI9xWImMqBzzzWnAnAZTgUJGU9S3PKAVyee1JuYANuqqzhzyMkGrC4ePFBA3LNIQT1qxb391YnZBKEXcJFO0Eo4BAZSRlWwT8wweaq7XwenFR3K7gFBI45pptbDVnoya0kjNzm8Qzws37xM4Min7wz7jI/GrMs6zENHFHDHGqxxQxjCxIowqKPQAACqFqpi4JypqWaZUwFU4PpRd2sEkr3JhMN3zbiwPXGKc53jPf3qtuUBX5OPXvTzKSg2YBJ4oGKqkNyMU/zo2by8/NUR8x2RMM7uQqCMZLMegAHU+1Lc2scCW0kV5bzyvLLFOkLbxCybPlLDgt8/IGQMYznID9nK1wdSN+V7iyorONpORVG6tUMgcKC+eorQC43HNQENnnpmoBaECqjpiQYfoBQ37v5cH8qkmUMwxww6+9QhiWIYlgBTGNK5BGTk9jUIhk3YODmrWzawYMSD2NBUgF2I/OgV7EEUAD5DZPpUwiKvuI+U/pUSIuSwPOfWplQmQNuyenNAaigSeduLDbjGMVKsZ35OMfWlV/m2krxRvJb5SMYosTqxckSLtzipi3PJ6dqYhONxYComljZ8A/MDQOxI4BfG7HeovG+pyaToyap4f0C11K3gTN6s80hlhx/HtTbmPpyPu9Dxgl4XdwevUGpre4kt7hJIJHjkToy54q6U1F6oitBzVouzPJZfjBqrEGDRNCt2GCCqTvyO+HlYV6X4K1LxTqPh4azrsNlHYXystqkenRAbd2C/mbSwOQQoznHJ7Vx/j/4cR6ok2reE7dY7wZe40uIcSdy8A/Uxjp/Dx8q9dpWlaVa2VneaI2p+H7qe3hlafSLt0SXcgOZIZNyuOemVBrsk6bjdaXOGCqKeutjRdm2naRn9abFI20q9WbyQSw2uLg3VwkWye7NolqZ33Md3lISq8FV4PO3Peqqpg/NXC4pM9FSbV2ORsSf7NOLYOcH6USDaAQaYxLj3qRjzk4Knj3oqEllwBRW0diuZdymzc/1qLzNpxU2N6kDjFRGLI56isBEhbGBTSwyOTzTUb5TzyKj++c9hTFclz82D1puSG600kLg96UtnimK5L5nQdc0yXG3I6GoTwxxyBTgwKH2o5QuiJXAJqUvhcrVSbcrblBNSISSD2NVYXMSEhmyTg1KJBswMVCxww44pHbj5QAadhXJElwGHWjzFPpmogcjHT6UxuDwfzosDGyDDHlcVWZiWIwMVMCSGBx65pPLxjnmnYtMgZVYY29aRYtpOauLF1yaUW+SKB8xVxiQHHbpViNfmB2nFTCLHJ7VZjRAM5P0pWFzkSL0ZRj0q/Gx2YPWqanDDHTv7VOGOBt5FKxLdyXqCM0sLvyGxt6VF5mYz60JK3TbxRYCzuGGAbFRk7pN3PTGKYuDnOBShip65FIETbsHH40z13HJpMFyWzjFKwYdgRTsO5IDk/LgjHepLaMzzSAeXHHEhklmlYJHEg6s7HhQPU1W4xhTg0uoWaeItOttCuLQTQtNlY45JIzLIThS+1huI7ZzjJx1NOKTepM20vdPN/HfxGQG407wjPL5bgxz6owKSSqeCkI6xxnnJ++w67QStdZ4AiWLwP4bQ/8ALW3muPoTcyp/KIVxniT4f293a6xrHhOTdplrcm2tYWJdr0Rr+/ljP9wMRtByWGecrg+jaOFtPC3hu3YDemlwt15/eAy/+1K7KrUadkcFBOVTmkT3JYqwXgg8UsLuMZ5HelT5lO8ZHpVywtrQwTJc3JS+e3e4s7cDJkRHVXdvRQCQPUg/3TXGoN7HoSqRjuVW+8SRgEUxgFxtHJprbnOGPFAAAwTzUFEhUOuM5PtUTwjABP51Jp8L3OoQWy4UzOEDMcBcnqT2A61LfI1rfvEjLNCMNHMnKyxsAyOvsykEexp2dr9CdL26leOFUB4JzSDIY7WHHb0p7y5BG2ogoRSQOtAxzJlt4/E0m8O2M7TjHFWrmwubbT7S6dMQXauYm7HaxVh9QR09CDVGCPksCCT0os9gjZ6omDsWClTxxmr9gyxfbEXT4L26mgYW8UhZd0q/MqgqQcsAUHUbmUkHGDSV+MMpB9qj+0usoaF2SZCGRh1Vh0P51ULKWpNR80dDH0Px34X1jaou5dFuj/yxv/miJ9FmUY/76VB711c1tNFBHM4DW8v+ruI3DxSf7rqSrfgTXhPxX0VdM8XSXFpD5djqiC+t0UcLvJDxj2WQOo9gD3rtvhZ4cv8ASIry8/tjUrS8tJjBqGkQ5iMLA/L9oVgQ6N/u47ZB4rqqUIW5locVLEVFLlep3MTMjAqxBU5BB5FS393NcyyXE7mWaT7zHGTxioLy5+0XMsmyKEuSdkShVHsAOgqFS2OTnFcZ3+ZLG7FCe47USbnX0NQFto7jNPEjHIDDmkBLExZdjHB7GlDBHAJyfXNRL0LZyaUYZs4APegaCZiX46UUj9aK1jsjCW7K8eVGaHbceCNvU0iNnPtTP9USDgo3b0NYG5BOCjbwfqKSN1PToRUsjbQwYFkqmGEUhQ8hhlapEXJWIJPPWkSQsMelMLZ4HftTGBEgP8WOKtIVybeeaQvnjOKIkJPIOKr3F3aRNiS4QMD06mr5SLkxbtknHpQGIb2NU5dXslIKtI5x0C1GNYibIS2majkDmNNDk4JpcckHvWWL27bJj06Q56cGni51M/c0xz/wE1XIHMi8C38I4psgJGRzVMXGpqQx0qTaOvymmm/usHdpcw+gNPkDmRcRWVvmXA96mI28leazTq5TG+wnUjtilbXYcjfb3Az144o5WHOX9+QSVJNSoxJBIYDvWemt6cBzvX/tnTxrGmEg+cR/wA1PKHOany7Dg0nynBxnFUU1OxbkXQx7ilOpWgHy3MfPvRyhcutn+AU+M8Ybg+1VFurfaMTRsT/tCpA6EfLIn/fVLlHclAIJIIZM04vtGR1quhKybN3X0qQPjIZSMd6OUdx0UgfJJ6VIxYn5BjiokIXJHOaUsGcbSQR+tTYLjzKdvJxipFdgAQ2ag4I+epF4GCpA7Giw7kpc5Bxmp4Q09hqcNvew6dez2zQQXUyOyQlmVXbCAtu8syBSBwxHTqKAJR8qd3tT93Uk446U4+67ikuZWZblaC3S2tdJDQ6fYRiC0U8MEUk7j/tMSWP+0xpt3cve3CvMsQZY0iVUUKAqIEUADgcKOlVllGAMqPekjO5/nKgZ60ndvUSsloSXl3a6Rpd1qmrFlsLYDcFO1pnOdkKH+82Dz2AZu2K81+HviS8134uw3+puvmX8VxaiNBhIw0DpHGgPRVOwAe3Wu88V+GbTxjrNpbza1d2eg2SsYoltFJVQu6aZ2343ELnp0VR2zXA+GfCepeHtQ8H+Kk2z23nwX88CZ8yCITcFh/EpRQxI6BuQOp7KUYqNkcVaUnO7R6P5p3YHQ96lGOCeT61JewGzvrm2IGYZGjOf9k4/pUcbbgQvFcXKehzGd4p1b+x/CGtX6EpOYhYwH/prOGU/lEJjnsdtZnww1ltb8HfZJGJvdGxGx7vbMTsP/AGyhPo0YHSoPiTpGreJNX0TwvoFm88kKi4uXJCIJ7jbsVnbCj92IyMn+NsCuc+Hel694dvtI8RpYSXej3ySRXEVswkla3LtFIDGDuyChYcdVU12xgvZ8rPPlVftedHp5YEYJGaaTuG09Km1G0eyvZYJgpKNgMvR16hh7EYI+tQEArz0risehzXOX8U+NG8P/EBbG93zaJJp9nHdRJyyboxMsqc43oZj6ZBZTjJx1Dx+VICjpNE6LLFNEcpNGRlXU+hH4jkHBBFeRfFC1u9Q+Ivis2lvNPFps7RTOilhEkOIssew+UDNeg/DjTfEWlp/wjPiK0jSzkPmWVz9qicWsjYODtY/unyM/wB0nd/ez21qfNHTc8+jVcZ+RtBnbOTxSomGHPJp21kkKEDcpwec801mcfeUZ9q4TvLF1plhrEOnS3sirdaNc/bLbK58wMADH/32sT88YV/WpL3dfX1tf2d3Fp3iGzTy4b+ZS8NzD3t7lVBLoRwDgkdOmCtYLtQN3psigkNurSNWSsZSpRle/Uv6p9lOpTmx2mDf8mM4x7bucemecdearDKHnkGo0wBnrQZCSBt4rNmydiSXGOBzTCQqdOaXIAwM01nBbBpWGmFuzchqlIDH5Tg1Ey4O5TSKec5pFIZIzhsZopJZBv6UVvHYxluwUclgcGmyOOSR9acSS+T0FRTYz8x47YrnRo2Ryudny9O9V5cMiMp4Xk1KrnLo3TGR71nXt6tqDFAPMnboq84raEbmc5Fid0gjEkjeWOuT3+lUH1SW4l8vTbZ5D2YjPPrW74a8C6hr8q3Golorc4PP9BXrvh3wrpuixKttApcdXYZJrdQMJVDyPS/BHiPWgJLgmGJh/HxxXaaV8JtPjjX7dM8r9Tt4FemImKmUVaijJ1GcjY/D7QLQDbZhz6uc1rxeGtJiA8uwtx/wAVtAU7FOxPMygmn28YASGNR6BRS/ZI16RqPwq6RSEU7C5mUfs0Y/gX8qabOI8+Wv5VeK0m2iwuYypdJtJDl7eFj6lBVZ/D+nspU2duQevyCt7ZRsosHOzlX8IaO3Wwg+m2q8ngrRG66bB+VdgUpClFiudnBv4B0PJP2Fee2eKpXPw50OXOLbZn0NejmMGojAPSiyHzs8ul+FujtyjTofY1Wl+Fdn/wAsbydPrzXrBgphipWQ/aM8el+GF2jZt9TYAdCc1C3w71qIEx6ojH0bNeymKm+XRZD9ozxSTwR4nX7tzEw/3qgk8L+KojhYoXx3BFe5eUKTyh6UuVD9ozwW40nxTGoD2CN9BUbQ+JI0G7SGOO4Br3wwj0pPJHpRyoftWfPxvNXjUmXSZjjrjNVxq8ynMun3CZ7AGvogwKewxULadbt1hjP1UUuRD9szwD+2osAPBcJ/wGnLrlqCMvIv+8te8Poli5Je0gJP/TMVBL4Y0iUYksLc/wDAAKXs0Htjx631SwvLDVbJtSjsnvLKS2iuJEZljL4VshQTgoXXgfxVfvtUsmuo/wCzLlRbWyR29tztYRxoqIfY7VFehy+AvD8pJawTJ9CRVSb4ZeH5Gytu8f8AutT5NLC9oubmOAuL/wC0XMs00wknlcyOxbJZickn8aXdlxt5GO1dhP8ACbSmfdDPcR/8CqnP8KmTm01OZf8AeqfZF+2RU07UZp/EGn3V5O0hjuYmJdsAAMPwAwKy4dOu9I8OadY6jBNa3MM12nlzIUZk+0Oyvg84OTj1xWtJ8N9ajH+j6sD/AL4qtL4L8UxN9+2uQPWjlfK0JNcyl2KLyyyvvkkMhwBlmycDgDmn28ix3EUjDeqOGK5xkA9KbdaTr1mP9L0p2UdWhOaz2vI4mxOksDf9NFIrP2bNuZM2rBbKXULy3kjS0sNVadLvBz/rwytIx6sRvLZ7Y4AGBVeW3uLTStDg1Nof7Ti0+OC6WCdJlDRlo0+dCVJMSRnr39aoCVWG9XVl9Qae0wCj1puUmrMiMEpXRMVH8LEU3JBxu5qt9oweR9Km81W5xWfKbEvmEDHU+tIWKgFuaarJ6imuAxzmlYRP5mcUFgDkmoNwJ+XH50zcScE0WGWi+VyOaaW3HLccVF5hQAc/hTt+8dyfelYLkyNgcnikZwD049agzkcmlVsYBGRRYOYkcLmimSSLu/CitI7GUnqLI+wk9+w9apTy4XKjKnnHoaluVIAPU9qqidY4Gd/4TwD3NZxVzSTIbu48p9kAZ55BgD0rufAHgZVKX2oqWkPzBTVf4d+Fjfzf2pfA7d2UUivXYY1RQFGAOAK6oRscc53EhhWNAqqAAOAKsKKRRT60MhwpwpgNKDQBKDS5qMNSg0wH5oNNzRmgQ6ikzSigQoFGKUUUCGkUhFPNNNMY3bRtp1LQBGY6jaOrNIRSC5VMdN8qrm32o20hplMxU3yzV/ZSGL2pFmeUpNlXmipnl0gKgSl2Va8ujZTArbKAlWdho2UCIQlOC1LspdtNCI9tGz2qULS4pgR7B6UeWKkxRQBE0KkcjNUb/R7O8Ui4toZR/toDWpRQO7R5/qvw50S8LMtuYGPeI4/Suavfhrdx7orDU2Fs38Mi5Zfoa9hdQRULRilZFe0aPDpvAXiG2OILuG4X0cYqrL4Z8SRcGyjkPqj17uYge1N+zj0pOKKVZngn9h+JF6aYc/71Rtp/iKL72lMfoa99NsPSontR6VPIh+2Z8/XEuqRL+90mcY6kZqmdYaLAms7hD/u19CyWanIIqpNpNtICHgib6qDR7ND9szwlddti3z+YnsVNTRarZyNxMAffivYJvC2mSgh7GFv+A1nXHgHRZs5swp9VNL2SK9sjzdLiJvuyofxp5buDke1dtN8NdMJJjMqfQ1nXHw225+y38iemRU+yH7ZHMO2Tz6UVqT/D3WN/7vUlK/SiqUNCHU1KEpH3s4A5NT+E9Dk8SaonylLKA5Ykdeai02yn8QaitlZIfJB/eSdsd69s0LSbfSbGO3towoUckdz61NOA6lQs2dtHbQJFCoVFGABVoCgLTsVsc4opabS5pgLRSZpM0AOzS5pmaTNAEoNLmowaUGgCTNKDTM0ZoEShqdmoQacGoESUlNzS5pgLS03NKKBDqWkFKKQC4pwFJTh0oY0KBRilFFSaDSKYVqXFNIoAixRipCKaRQSMxRinYopgNxSYp1IaYCUUlGaAA0maDTc0AOzRmm5ozQA41Gwp2aQ0CGUYpaXFAhMUjCnUGgCJkBqMxip6SgZEsQp3lD0qUClxQMrvGMdKryRCrxFQuKBFExCirJXmiiwrmb4Y8P22hWCwQKPMPLv3JrbApe1LTtYbbDFGKWiiwrjTSU6mmiwrhSUUtFgTEpM0tFFh3CnCm0tA7jqXNNFLQFxaAaSgUAPBpwNMFOpiFzThTaVaLCJBSim0+iwXDNOBpmaM0WC5JmnZqKlBqbDuSUU3NGaLBzAaYTTjTDRYLhmkzTaKdguLmkJopDRYLiUmaXvSUWAQ0lKabRYLi0UlFAXCijvRRYLhRRRTsAUhpaRqLCEoFFAosFxRS0lFKw7iGonqU1C/WgBhooNFMR//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lower extremity involvement, with several Fusarium skin lesions of different types and ages. Small macular lesions, papular lesions of different sizes, and two target lesions: central necrosis surrounded by an erythematous base, an area of normal skin, and an outer rim of thin erythema (arrows). Patient was a 32-year-old woman with relapsed leukemia who had undergone allogeneic bone marrow transplantation and developed disseminated and fatal fusarial infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immuncompromised hosts: Implications for diagnosis and management. Clin Infect Dis 2002; 35:909 by permission of Oxford University Press. Copyright &copy; 2002.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_43_5809=[""].join("\n");
var outline_f5_43_5809=null;
var title_f5_43_5810="Pylorus-preserving pancreaticoduodenectomy";
var content_f5_43_5810=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Pylorus-preserving pancreaticoduodenectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_43_5810=[""].join("\n");
var outline_f5_43_5810=null;
var title_f5_43_5811="Advanced RP";
var content_f5_43_5811=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53849&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Advanced retinitis pigmentosa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Loss of the retinal pigment epithelium and choriocapillaris reveals the underlying large choroidal vessels seen as orange stripes throughout the ocular fundus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_43_5811=[""].join("\n");
var outline_f5_43_5811=null;
var title_f5_43_5812="Simethicone: Patient drug information";
var content_f5_43_5812=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Simethicone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/35/33332?source=see_link\">",
"     see \"Simethicone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/9/27795?source=see_link\">",
"     see \"Simethicone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Equalizer Gas Relief [OTC];",
"     </li>",
"     <li>",
"      Gas Free Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Gas Relief Ultra Strength [OTC];",
"     </li>",
"     <li>",
"      Gas-X&reg; Children's Tongue Twisters&trade; [OTC];",
"     </li>",
"     <li>",
"      Gas-X&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Gas-X&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Gas-X&reg; Thin Strips&trade; [OTC];",
"     </li>",
"     <li>",
"      Gas-X&reg; [OTC];",
"     </li>",
"     <li>",
"      Gax-X&reg; Infant [OTC];",
"     </li>",
"     <li>",
"      Infantaire Gas [OTC];",
"     </li>",
"     <li>",
"      Infants Gas Relief Drops [OTC] [DSC];",
"     </li>",
"     <li>",
"      Little Tummys&reg; Gas Relief [OTC];",
"     </li>",
"     <li>",
"      Mi-Acid Gas Relief [OTC];",
"     </li>",
"     <li>",
"      Mylanta&reg; Gas Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Mylicon&reg; Infants' [OTC];",
"     </li>",
"     <li>",
"      Mytab Gas Maximum [OTC];",
"     </li>",
"     <li>",
"      Mytab Gas [OTC];",
"     </li>",
"     <li>",
"      Phazyme&reg; Ultra Strength [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F221169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ovol&reg;;",
"     </li>",
"     <li>",
"      Phazyme&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691592",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease too much gas in the GI (gastrointestinal) tract.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702925",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to simethicone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695845",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take after meals and at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Chewable tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694595",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chew or crush tablet well. Mix crushed tablet with food. Do not swallow tablet whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3727942",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral strip:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695517",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Place oral strip on your tongue and let melt.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695304",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Liquid (drops) may be mixed with water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11446 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-1A66C01F0E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_43_5812=[""].join("\n");
var outline_f5_43_5812=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221168\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221169\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013198\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013197\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013202\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013204\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013200\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013201\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013205\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013206\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/35/33332?source=related_link\">",
"      Simethicone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/9/27795?source=related_link\">",
"      Simethicone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_43_5813="Septic pulmonary emboli CT";
var content_f5_43_5813=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Septic pulmonary emboli",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 609px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan of the chest shows multiple nodules, most in subpleural locations and many with cavitation, in an intravenous drug user with tricuspid endocarditis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_43_5813=[""].join("\n");
var outline_f5_43_5813=null;
var title_f5_43_5814="Sargramostim: Drug information";
var content_f5_43_5814=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sargramostim: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/6/25700?source=see_link\">",
"    see \"Sargramostim: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/49/4885?source=see_link\">",
"    see \"Sargramostim: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Leukine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F220033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Leukine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F220055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Colony Stimulating Factor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F220035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     I.V. infusion over &ge;2 hours or SubQ:",
"     <b>",
"      Rounding the dose to the nearest vial size enhances patient convenience and reduces costs without clinical detrement.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Myeloid reconstitution after allogeneic or autologous bone marrow transplant:",
"     </b>",
"     I.V.: 250 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day (over 2 hours), begin 2-4 hours after the marrow infusion and &ge;24 hours after chemotherapy or radiotherapy, when the post marrow infusion ANC is &lt;500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     , and continue until ANC &gt;1500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     for 3 consecutive days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If a severe adverse reaction occurs, reduce the dose by 50% or temporarily discontinue until the reaction abates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If blast cells appear or progression of the underlying disease occurs, discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If ANC &gt;20,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     , interrupt treatment or reduce the dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Neutrophil recovery following chemotherapy in AML:",
"     </b>",
"     I.V.: 250 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day (over 4 hours) starting approximately on day 11 or 4 days following the completion of induction chemotherapy, if day 10 bone marrow is hypoplastic with &lt;5% blasts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If a second cycle of chemotherapy is necessary, administer ~4 days after the completion of chemotherapy if the bone marrow is hypoplastic with &lt;5% blasts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continue sargramostim until ANC is &gt;1500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     for 3 consecutive days or a maximum of 42 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Discontinue sargramostim immediately if leukemic regrowth occurs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If a severe adverse reaction occurs, reduce the dose by 50% or temporarily discontinue the dose until the reaction abates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If ANC &gt;20,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     , interrupt treatment or reduce the dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mobilization of peripheral blood progenitor cells:",
"     </b>",
"     I.V., SubQ: 250 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day I.V. over 24 hours or SubQ once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continue the same dose through the period of PBPC collection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     The optimal schedule for PBPC collection has not been established (usually begun by day 5 and performed daily until protocol specified targets are achieved)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If WBC &gt;50,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     , reduce the dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If adequate numbers of progenitor cells are not collected, consider other mobilization therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Postperipheral blood progenitor cell transplantation:",
"     </b>",
"     I.V., SubQ: 250 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day I.V. over 24 hours or SubQ once daily beginning immediately following infusion of progenitor cells and continuing until ANC is &gt;1500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     for 3 consecutive days is attained",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      BMT failure or engraftment delay:",
"     </b>",
"     I.V.: 250 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day over 2 hours for 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     May be repeated after 7 days off therapy if engraftment has not occurred",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If engraftment still has not occurred, a third course of 500 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 14 days may be tried after another 7 days off therapy; if there is still no improvement, it is unlikely that further dose escalation will be beneficial",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If a severe adverse reaction occurs, reduce the dose by 50% or temporarily discontinue the dose until the reaction abates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If blast cells appear or disease progression occurs, discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If ANC &gt;20,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     , interrupt treatment or reduce the dose by 50%",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F220048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/49/4885?source=see_link\">",
"      see \"Sargramostim: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage not established in children (unlabeled use). Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F220036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F220011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Leukine&reg;: 250 mcg [contains sucrose 10 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Leukine&reg;: 500 mcg/mL (1 mL) [contains benzyl alcohol, sucrose 10 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F219996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F220015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Can premedicate with analgesics and antipyretics (eg, acetaminophen) to control adverse events (eg, fever, chills, myalgia, etc); control bone pain with non-narcotic analgesics. Sargramostim is administered as a subcutaneous injection or intravenous infusion; intravenous infusion should be over 2-24 hours; continuous infusions may be more effective than short infusion or bolus injection. An in-line membrane filter should",
"     <b>",
"      NOT",
"     </b>",
"     be used for intravenous administration. When administering GM-CSF subcutaneously, rotate injection sites.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F220062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, sterile water for injection, bacteriostatic water;",
"     <b>",
"      incompatible",
"     </b>",
"     with dextrose-containing solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amikacin, aminophylline, aztreonam, bleomycin, butorphanol, calcium gluconate, carboplatin, carmustine, cefazolin, cefepime, cefotaxime, cefotetan, cefuroxime, cimetidine, cisplatin, clindamycin, cyclophosphamide, cyclosporine, cytarabine, dacarbazine, dactinomycin, dexamethasone sodium phosphate, diphenhydramine, dopamine, doxorubicin, doxycycline, droperidol, etoposide, famotidine, fentanyl, floxuridine, fluconazole, fluorouracil, furosemide, gentamicin, granisetron, heparin, ifosfamide, immune globulin, magnesium sulfate, mannitol, mechlorethamine, meperidine, mesna, methotrexate, metoclopramide, metronidazole, minocycline, mitoxantrone, pentostatin, piperacillin/tazobactam, potassium chloride, prochlorperazine edisylate, promethazine, ranitidine, teniposide, ticarcillin/clavulanate, trimethoprim/sulfamethoxazole, vinblastine, vincristine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, ampicillin, ampicillin/sulbactam, chlorpromazine, haloperidol, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, imipenem/cilastatin, lorazepam, methylprednisolone sodium succinate, mitomycin, morphine, nalbuphine, ondansetron, piperacillin, sodium bicarbonate, tobramycin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Amphotericin B, amsacrine, ceftazidime, ceftriaxone, ganciclovir, idarubicin, vancomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F220014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute myelogenous leukemia (AML)",
"     </b>",
"     following induction chemotherapy in older adults (&ge;55 years of age) to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bone marrow transplant (allogeneic or autologous) failure or engraftment delay",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Myeloid reconstitution after allogeneic bone marrow transplantation",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Myeloid reconstitution after autologous bone marrow transplantation:",
"     </b>",
"     Non-Hodgkin's lymphoma (NHL), acute lymphoblastic leukemia (ALL), Hodgkin's lymphoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Peripheral stem cell transplantation:",
"     </b>",
"     Mobilization and myeloid reconstitution following autologous peripheral stem cell transplantation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F220065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Leukine&reg; may be confused with Leukeran&reg;, leucovorin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F220053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (34%), pericardial effusion (4% to 25%), edema (13% to 25%), chest pain (15%), peripheral edema (11%), tachycardia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (81%), malaise (57%), headache (26%), chills (25%), anxiety (11%), insomnia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (44%), pruritus (23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (25%), hypercholesterolemia (17%), hypomagnesemia (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (&le;89%), nausea (58% to 70%), vomiting (46% to 70%), abdominal pain (38%), weight loss (37%), anorexia (13%), hematemesis (13%), dysphagia (11%), gastrointestinal hemorrhage (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract disorder (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Hyperbilirubinemia (30%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (66%), bone pain (21%), arthralgia (11% to 21%) myalgia (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Eye hemorrhage (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: BUN increased (23%), serum creatinine increased (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (23%), epistaxis (17%), dyspnea (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Respiratory: Pleural effusion (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction, anaphylaxis, arrhythmia, capillary leak syndrome, constipation, dizziness, eosinophilia; first-dose effect (syndrome with respiratory distress, hypoxia, flushing, hypotension, syncope, and/or tachycardia occurring with the first dose of a treatment cycle); injection site reaction, lethargy, leukocytosis, liver function abnormalities (transient),  pain, pericarditis, prothrombin time prolonged, rigors, sore throat, supraventricular arrhythmia (transient), thrombocytosis, thrombophlebitis, thrombosis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F220018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sargramostim, yeast-derived products, or any component of the formulation; concurrent (24 hours preceding/following) myelosuppressive chemotherapy or radiation therapy; patients with excessive (&ge;10%) leukemic myeloid blasts in bone marrow or peripheral blood",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F220000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic reactions: Anaphylaxis or other serious allergic reactions have been reported; discontinue immediately if occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac disease: Use with caution in patients with pre-existing cardiac problems or HF. Transient supraventricular arrhythmias have been reported in patients with history of arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid retention: Edema, capillary leak syndrome, pleural and/or pericardial effusion have been reported. Use with caution in patients with pre-existing fluid retention; may worsen.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; monitor hepatic function in patients with history of hepatic dysfunction. Bilirubin and transaminase elevations have been observed with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; monitor renal function in patients with history of renal dysfunction. Serum creatinine elevations have been observed with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory problems: Dyspnea may occur; monitor respiratory symptoms during and following infusion. Decrease infusion rate by 50% if dyspnea occurs; discontinue with persistent dyspnea. Use with caution in patients with hypoxia, pulmonary infiltrates, or pre-existing lung disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cytotoxic chemotherapy/radiotherapy: Simultaneous administration, or administration 24 hours preceding/following cytotoxic chemotherapy or radiotherapy is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Solution contains benzyl alcohol which has been associated with \"gasping syndrome\" in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood counts: If there is a rapid increase in blood counts (ANC &gt;20,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , WBC &gt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , or platelets &gt;500,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ), decrease dose by 50% or discontinue drug (counts will fall to normal within 3-7 days after discontinuing drug).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; First dose effect: There is a &ldquo;first-dose effect&rdquo; (refer to Adverse Reactions for details) which is seen (rarely) with the first dose of a cycle and does not usually occur with subsequent doses within that cycle.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor growth factor: May potentially act as a growth factor for any tumor type, particularly myeloid malignancies; caution should be exercised when using in any malignancy with myeloid characteristics. Tumors of nonhematopoietic origin may have surface receptors for sargramostim. Discontinue use if disease progression occurs during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bleomycin: Sargramostim may enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F220007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F220021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clinical effects to the fetus: Animal reproduction studies have not been conducted. It is not known whether sargramostim can cause fetal harm when administered to a pregnant woman or can affect reproductive capability. Sargramostim should be given to a pregnant woman only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F220042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Leukine Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mcg/mL (1 mL): $410.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Leukine Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mcg (1): $243.92",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F220009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs, hydration status, weight, CBC with differential twice weekly during therapy, renal/liver function tests at least biweekly during therapy (in patients displaying renal or hepatic dysfunction prior to initiation of treatment), pulmonary function",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F220012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excessive leukocytosis: ANC &gt;20,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or WBC &gt;50,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Interberin (AT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F219999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates proliferation, differentiation and functional activity of neutrophils, eosinophils, monocytes, and macrophages, as indicated.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F220017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Increase in WBC: 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: WBCs return to baseline within 1 week of discontinuing drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.V.: 60 minutes; SubQ: 2.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: SubQ: 1-3 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Lieschke GJ and Burgess AW, &ldquo;Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor,&rdquo; (1)",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1992, 327(1):28-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/43/5814/abstract-text/1375975/pubmed\" id=\"1375975\" target=\"_blank\">",
"        1375975",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lieschke GJ and Burgess AW, &ldquo;Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor,&rdquo; (2)",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1992, 327(2):99-106.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/43/5814/abstract-text/1376442/pubmed\" id=\"1376442\" target=\"_blank\">",
"        1376442",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mayer D and Bednarczyk EM, &ldquo;Interaction of Colony-Stimulating Factors and Fluorodeoxyglucose F",
"      <sup>",
"       18",
"      </sup>",
"      Positron Emission Tomography,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2002, 36(11):1796-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/43/5814/abstract-text/12398579/pubmed\" id=\"12398579\" target=\"_blank\">",
"        12398579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith TJ, Khatcheressian J, Lyman GH, et al, &ldquo;2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(19):3187-205.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/43/5814/abstract-text/16682719/pubmed\" id=\"16682719\" target=\"_blank\">",
"        16682719",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stute N, Furman WL, Schell M, et al, &ldquo;Pharmacokinetics of Recombinant Human Granulocyte - Macrophage Colony - Stimulating Factor in Children After Intravenous and Subcutaneous Administration,&rdquo;",
"      <i>",
"       J Pharm Sci",
"      </i>",
"      , 1995, 84(7):824-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/43/5814/abstract-text/7562431/pubmed\" id=\"7562431\" target=\"_blank\">",
"        7562431",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,&rdquo; August 16, 2010. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9878 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-2AD339225F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_43_5814=[""].join("\n");
var outline_f5_43_5814=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220032\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220033\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220055\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220035\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220048\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220036\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220011\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219996\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220015\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220062\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220014\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220065\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220053\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220018\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220000\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300028\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222861\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220007\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220021\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220042\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323819\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220009\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220012\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038802\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219999\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220017\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9878\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9878|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/6/25700?source=related_link\">",
"      Sargramostim: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/49/4885?source=related_link\">",
"      Sargramostim: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_43_5815="Color coded tissue Doppler";
var content_f5_43_5815=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59526%7ECARD%2F58091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59526%7ECARD%2F58091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Color-coded tissue Doppler echocardiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 417px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The color-coded tissue Doppler echocardiography&nbsp;image of the normal left ventricle is obtained from the apical four chamber view (panel C); the corresponding color tissue Doppler M-mode through medial mitral annulus is seen in panel B and the mitral annular time-velocity plot is shown in panel A.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Example of tissue Doppler echocardiographic imaging of left ventricle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown is an example of low velocity Doppler imaging of myocardial motion, known as tissue Doppler. In this example, velocities of up to 8 cm/sec are color coded according to direction and velocity. As shown in the upper left velocity display, myocardial motion towards the transducer is coded in shades of red and orange (hot colors) and away motion in blue and green (cool colors). The normal short axis precordial image at the top of the screen is shown in mid systole with the anterseptal walls moving away from the transducer and the posteroinferior walls toward. An M-mode tracing details the midseptum and the posterior wall. Note that at peak systole both opposing walls accelerate to at least 8 m/sec and also that there is a gradient of velocity within the myocardium (endocardial layers fastest).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_43_5815=[""].join("\n");
var outline_f5_43_5815=null;
var title_f5_43_5816="Diagnostic approach to the neuropsychiatric manifestations of systemic lupus erythematosus";
var content_f5_43_5816=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic approach to the neuropsychiatric manifestations of systemic lupus erythematosus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/43/5816/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/43/5816/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/43/5816/contributors\">",
"     Shahram Khoshbin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/43/5816/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/43/5816/contributors\">",
"     Jonathan M Silver, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/43/5816/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/43/5816/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/43/5816/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/43/5816/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 10, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic lupus erythematosus (SLE) may involve the nervous system and present with a number of different neurologic and psychiatric syndromes (",
"    <a class=\"graphic graphic_table graphicRef63649 \" href=\"UTD.htm?17/40/18061\">",
"     table 1",
"    </a>",
"    ). These neuropsychiatric manifestations may mimic symptoms due to intercurrent illness, medication use, and functional disturbances (",
"    <a class=\"graphic graphic_table graphicRef81577 \" href=\"UTD.htm?21/44/22220\">",
"     table 2",
"    </a>",
"    ). The term lupus cerebritis refers to the neuropsychiatric manifestations of lupus that appear to have an organic rather than psychiatric basis, rather than a specific pathophysiologic mechanism.",
"   </p>",
"   <p>",
"    Although it would be desirable to have diagnostic tests that establish a specific diagnosis of neuropsychiatric lupus, such tests do not exist. Thus, the approach to patients with neuropsychiatric symptoms consists of studies that establish the diagnosis of SLE, distinguish between organic and functional etiologies, and exclude symptoms not due to SLE. A typical workup for the patient with acutely altered behavior and mental status is outlined in Table 3 (",
"    <a class=\"graphic graphic_table graphicRef77325 \" href=\"UTD.htm?33/35/34363\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Diagnostic testing, and the interpretation of such testing, in patients suspected of having neuropsychiatric manifestations of SLE are reviewed here. Details of the clinical neurologic and psychiatric manifestations of SLE are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/11/33978?source=see_link\">",
"     \"Neurologic manifestations of systemic lupus erythematosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38631?source=see_link\">",
"     \"Neuropsychiatric manifestations of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SEROLOGIC STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic tests are typically used to help establish the diagnosis of SLE. The antinuclear antibody (ANA) titer is positive in virtually all patients with this disorder. However, the presence of ANA is not a very specific finding, and many non-SLE patients have symptoms such as headache or fatigue with only a weakly positive ANA. Serum levels of anti-DNA and anti-Sm antibodies and low levels of complement are useful in this setting to corroborate the diagnosis of SLE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=see_link\">",
"     \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the patient with established SLE, an association between neuropsychiatric symptoms and specific antibodies has been demonstrated (by some) in a few circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antiphospholipid antibodies have been associated with cerebrovascular accidents, vascular dementia, seizures, thromboses, chorea, headache, and transverse myelitis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/4-8\">",
"       4-8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antiribosomal P antibodies have been associated with psychosis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/9,10\">",
"       9,10",
"      </a>",
"      ] and with severe depression in some studies [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/4,11\">",
"       4,11",
"      </a>",
"      ]. However, others were unable to confirm an association of these psychiatric disorders with the presence of these antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/12\">",
"       12",
"      </a>",
"      ]. A meta-analysis published in 2006 reported that antiribosomal P antibodies have limited sensitivity and specificity (23 and 80 percent, respectively) for neuropsychiatric lupus and do not differentiate between subsets (eg, psychosis versus depression) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/13\">",
"       13",
"      </a>",
"      ]. We do not use them in clinical practice to make a diagnosis of, nor to exclude, neuropsychiatric lupus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27718?source=see_link\">",
"       \"Antiribosomal P protein antibodies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The roles, if any, of antineuronal, anti-neural tissue-specific, and anti-N-methyl-D-aspartate receptor (NMDA) antibodies are uncertain. Antibodies with these specificities are found in patients with many neuropsychiatric manifestations, including cognitive dysfunction and depression but studies of associations with specific deficits or mood disorders have been inconclusive or reached disparate conclusions [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/2,4,14-23\">",
"       2,4,14-23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antiganglioside antibodies have been observed in some with migraine and other neuropsychiatric symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/24\">",
"       24",
"      </a>",
"      ] as well as some patients with peripheral neuropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antibodies to microtubule-associated protein 2 were found in a high percentage (63 to 76 percent) of patients with neuropsychiatric SLE in two small case series [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. This finding distinguished such patients from control groups, including those with SLE and no neuropsychiatric symptoms, other neurologic diseases (eg, multiple sclerosis, cerebrovascular disease), and healthy controls, in which these were found in only a few percent. In the latter study, antibodies to Hsp70-71 and triosephosphate isomerase were also found in 63 percent of 16 patients with neuropsychiatric SLE [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PSYCHOLOGIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychometric testing can be helpful to differentiate functional from organic disease. A battery of 11 or 12 tests, that require from one to four hours to complete; the shorter 11-test series is reasonably sensitive and specific, however, the latter is better able to detect selective cognitive deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/27\">",
"     27",
"    </a>",
"    ]. These tests should be supplemented with a psychiatric interview when studies are equivocal [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Computer assisted assessment of cognitive function has been used to follow the performance of patient with SLE. An example is the Automated Neuropsychological Assessment Metrics (ANAM) which was developed as a language-independent method for this purpose and has been validated in at least one study in patient with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CEREBROSPINAL FLUID ANALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine evaluation of the cerebrospinal fluid (CSF) may be normal in patients with CNS lupus, except in cases of aseptic meningitis, vasculitis, and transverse myelitis. Some reports, however, have noted immunologic abnormalities including elevated levels of anti-DNA antibodies, IgG, oligoclonal banding, immune complexes, interleukin-6, the chemokine CXCL10, and markers of B-cell activation (eg, a proliferation-inducing ligand [APRIL] and B-cell activating factor of TNF family [BAFF]) which may roughly correlate with neuropsychiatric disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/4,31-34\">",
"     4,31-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One prospective study, for example, evaluated 52 patients hospitalized with diffuse or complex neuropsychiatric disease; all 52 had an abnormal CSF IgG index, oligoclonal bands, and increased CSF levels of antineuronal antibodies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serum antiribosomal-P antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/4\">",
"     4",
"    </a>",
"    ]. Sensitivity for this triad of tests was 100 percent, while specificity was 86 percent. The authors concluded that these findings both suggest a role for autoantibodies in the pathogenesis of diffuse CNS lupus and that these tests can be followed serially since they appeared to correlate with clinical responses to therapy.",
"   </p>",
"   <p>",
"    CSF levels of glial fibrillary acidic protein (GFAP), a product of neuroglia, and neurofilament triplet protein (NFL) are higher in those with CNS lupus than controls; mean elevations of three and seven fold, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/35\">",
"     35",
"    </a>",
"    ]. The increase in CSF concentrations of NFL was accompanied by generally higher intrathecal concentrations of interleukin-6 (IL-6), IL-8, oligoclonal immunoglobulins, and a higher CSF to serum albumin ratio. Levels of both GFAP and NFL were correlated with the degree of abnormality found on MRI. Further study of these putative markers of CNS lupus are needed. They are not specific for SLE and are elevated in other inflammatory CNS disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ELECTROENCEPHALOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 80 percent of patients with active CNS lupus will have an abnormal routine EEG or EEG mapping [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/29,36\">",
"     29,36",
"    </a>",
"    ]. Diffuse slow wave activity is the pattern most typically associated with encephalopathy, while focal changes may be seen in patients with seizure disorders or focal neurologic problems.",
"   </p>",
"   <p>",
"    The specificity of the EEG, however, is not as high as its sensitivity. Abnormal electroencephalograms have also been noted in patients with neurologic abnormalities with or without CNS lupus, and in those with active and inactive lesions. Evoked potentials and evoked potential mapping may be even more sensitive in detecting abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Quantitative EEG may also be an improvement over the conventional EEG. In one study of 52 patients, for example, the quantitative EEG was abnormal in 74 percent of patients judged to have neuropsychiatric SLE by other criteria, and in 28 percent of patients with no active evidence of CNS involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/37\">",
"     37",
"    </a>",
"    ]. Overall sensitivity was 87 percent, and specificity was 75 percent. Quantitative EEG is not widely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     IMAGING STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of imaging methods are available for use in the diagnosis of neuropsychiatric SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/38\">",
"     38",
"    </a>",
"    ]. CT scanning and magnetic resonance imaging (MRI) are the most useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     CT scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT scans are useful for detecting structural and focal abnormalities (such as",
"    <span class=\"nowrap\">",
"     infarcts/hypodense",
"    </span>",
"    areas, hemorrhage, tumors, cerebral calcification, abscess, and basilar meningitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/38\">",
"     38",
"    </a>",
"    ]. Brain atrophy has been noted in some patients; this finding has been thought by some (but disputed by others) to reflect the effects of steroid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/6\">",
"     6",
"    </a>",
"    ] or age [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/4\">",
"     4",
"    </a>",
"    ]. We have seen brain atrophy out of proportion to a patient's age, and prior to steroid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is more sensitive than CT, and may reveal abnormalities that reflect focal neuropsychiatric lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. However, MRI may also reveal white matter lesions or periventricular hyperintensities in patients with SLE who do not have neuropsychiatric symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/42\">",
"     42",
"    </a>",
"    ]. These white matter abnormalities may be difficult to interpret since they are present in 20 percent of the population younger than age 50, and in 90 percent of people older than age 70 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/6,41\">",
"     6,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Numerous studies have investigated the usefulness of MRI in patients with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/43-48\">",
"     43-48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 21 patients with SLE, 43 percent had high signal intensity, and 29 percent had large lesions; their presence correlated with disease activity as assessed by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report of 40 randomly selected patients with SLE, 15 had abnormal findings consisting of multiple widespread small-sized infarcts or increased signal in the white matter on T2 weighted images [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/48\">",
"       48",
"      </a>",
"      ]. Only seven of these patients had neuropsychiatric symptoms. These small infarcts can mimic multiple sclerosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75730 \" href=\"UTD.htm?22/9/22687\">",
"       image 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/41\">",
"       41",
"      </a>",
"      ]. They are frequently associated with antiphospholipid antibodies and livedo reticularis but not necessarily with neurologic symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with acute diffuse manifestations (seizures, psychosis, coma) may have longer T2 of the gray matter, suggesting cerebral edema [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acute, reversible lesions are characterized by the lack of discrete borders, intermediate intensity on T2-weighted images, intermediate size, a lacy filamentous pattern (which follows the gray-white matter junction along the sulci and gyri), and overlying or adjacent gray matter hyperintensity [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with SLE tend to have diminished cerebral and corpus callosal volume when compared to healthy persons; these MRI features, reported in a study of 155 patients, do not appear to be associated with cumulative glucocorticoid dose or the presence of antiphospholipid antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/49\">",
"       49",
"      </a>",
"      ]. The clinical significance of these findings are uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MRI is the most useful neuroimaging study in patients with SLE, particularly in those with focal neurologic defects, seizures, chronic cognitive dysfunction, or the antiphospholipid syndrome and neurologic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/38\">",
"     38",
"    </a>",
"    ]; it is less useful in patients with affective disorders, confusional states, or headache. Although MRI frequently detects clinically silent lesions, we have found the correlation with neuropsychiatric symptoms to be quite good.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Single photon emission computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;While SPECT scanning has been advocated by some to be more sensitive than MRI for detecting brain abnormalities in patients with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/38\">",
"     38",
"    </a>",
"    ], published reports provide conflicting data. One study of 20 patients with SLE demonstrated SPECT scan abnormalities in 9 of 10 patients with overt CNS disease, and no SPECT scan abnormalities in 9 of 10 patients without CNS symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/50\">",
"     50",
"    </a>",
"    ]. In another study, 30 of 37 patients with NPSLE demonstrated brain SPECT scan abnormalities, specifically, reduced perfusion in the watershed area of the frontal lobes, the severity of which correlated with the severity of cognitive dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/51\">",
"     51",
"    </a>",
"    ]. However, three other studies involving 94 patients did not demonstrate an association between SPECT scan abnormalities and neuropsychiatric manifestations of SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. SPECT has poor specificity in differentiating neuropsychiatric from non-neuropsychiatric lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/55\">",
"     55",
"    </a>",
"    ]. Our own unpublished observations also suggest that this modality does not correlate well with the clinical manifestations of CNS lupus, and should only be used for research purposes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous other studies have been used or studied in patients with SLE.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although angiography has been used historically to demonstrate vasculitis, it has limited sensitivity for detecting typical small vessel disease. Magnetic resonance angiography is also unable to accurately demonstrate these lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/38,56\">",
"       38,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      31P magnetic resonance spectroscopy (MRS) has been used to monitor changes in ATP and phosphocreatine during acute episodes of CNS lupus [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/57\">",
"       57",
"      </a>",
"      ], and proton NMR has been used to study anatomic changes in the brains of SLE patients with brain atrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/58\">",
"       58",
"      </a>",
"      ]. Another technique, 1H MR spectroscopy, reportedly detects neurometabolic changes prior to irreversible neurologic damage [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/59\">",
"       59",
"      </a>",
"      ]. While it has been proposed that MRS can detect and measure brain injury that is not evident by MRI, can determine whether cognitive decline has an organic basis, and whether or not a lesion seen on MRI corresponds to a clinically relevant brain injury [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/55\">",
"       55",
"      </a>",
"      ], experience remains limited with these techniques [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/38\">",
"       38",
"      </a>",
"      ] and unless promising results are confirmed by larger studies, the use of MRS in the clinical evaluation of neuropsychiatric SLE in not recommended.",
"     </li>",
"     <li>",
"      Position emission tomography (PET), using radiolabeled oxygen to assess brain cell metabolism, radiolabeled CO2 to evaluate cerebral vascular blood flow, and radiolabeled glucose, has demonstrated abnormalities of cell metabolism and regional blood flow in patients with SLE [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/60,61\">",
"       60,61",
"      </a>",
"      ]. However, this test is expensive, does not provide diagnostic information beyond that obtained with MRI, and is technically difficult to perform. PET is therefore",
"      <strong>",
"       not",
"      </strong>",
"      commonly used for diagnostic purposes [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Radionuclide brain scanning is generally not useful [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Limited evidence suggests that magnetization transfer imaging is more sensitive than MRI, particularly when quantifying brain damage, especially in patients with anti-cardiolipin antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/62,63\">",
"       62,63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Transcranial Doppler ultrasonography has been used to assess for signals indicative of microembolic matter in the cerebral circulation. In one study of 53 patients with SLE, ultrasonographic evidence of microemboli were detected much more frequently in the 25 patients with neuropsychiatric manifestations than those without such features [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5816/abstract/64\">",
"       64",
"      </a>",
"      ]. These signals were also more common in patients with SLE and elevated levels of anti-phospholipid antibodies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our recommended approach to the evaluation of neuropsychiatric disease in SLE is summarized in the algorithm in Table 3 (",
"    <a class=\"graphic graphic_table graphicRef77325 \" href=\"UTD.htm?33/35/34363\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/1\">",
"      Greenwood DL, Gitlits VM, Alderuccio F, et al. Autoantibodies in neuropsychiatric lupus. Autoimmunity 2002; 35:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/2\">",
"      Sen&eacute;cal JL, Raymond Y. The pathogenesis of neuropsychiatric manifestations in systemic lupus erythematosus: a disease in search of autoantibodies, or autoantibodies in search of a disease? J Rheumatol 2004; 31:2093.",
"     </a>",
"    </li>",
"    <li>",
"     Zandman-Goddard, G, Chapman, J, Shoenfeld, Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 2007:36:297.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/4\">",
"      West SG, Emlen W, Wener MH, Kotzin BL. Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 1995; 99:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/5\">",
"      Asherson RA, Mercey D, Phillips G, et al. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis 1987; 46:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/6\">",
"      Boumpas DT, Austin HA 3rd, Fessler BJ, et al. Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 1995; 122:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/7\">",
"      Toubi E, Khamashta MA, Panarra A, Hughes GR. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med 1995; 99:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/8\">",
"      Sanna G, Bertolaccini ML, Cuadrado MJ, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003; 30:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/9\">",
"      Bonfa E, Golombek SJ, Kaufman LD, et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987; 317:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/10\">",
"      Nojima Y, Minota S, Yamada A, et al. Correlation of antibodies to ribosomal P protein with psychosis in patients with systemic lupus erythematosus. Ann Rheum Dis 1992; 51:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/11\">",
"      van Dam A, Nossent H, de Jong J, et al. Diagnostic value of antibodies against ribosomal phosphoproteins. A cross sectional and longitudinal study. J Rheumatol 1991; 18:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/12\">",
"      Gerli R, Caponi L, Tincani A, et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) 2002; 41:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/13\">",
"      Karassa FB, Afeltra A, Ambrozic A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 2006; 54:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/14\">",
"      West SG. Neuropsychiatric lupus. Rheum Dis Clin North Am 1994; 20:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/15\">",
"      Denburg SD, Behmann SA, Carbotte RM, Denburg JA. Lymphocyte antigens in neuropsychiatric systemic lupus erythematosus. Relationship of lymphocyte antibody specificities to clinical disease. Arthritis Rheum 1994; 37:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/16\">",
"      Hanson VG, Horowitz M, Rosenbluth D, et al. Systemic lupus erythematosus patients with central nervous system involvement show autoantibodies to a 50-kD neuronal membrane protein. J Exp Med 1992; 176:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/17\">",
"      Omdal R, Brokstad K, Waterloo K, et al. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol 2005; 12:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/18\">",
"      Husebye ES, Sthoeger ZM, Dayan M, et al. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann Rheum Dis 2005; 64:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/19\">",
"      Lapteva L, Nowak M, Yarboro CH, et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 2006; 54:2505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/20\">",
"      Harrison MJ, Ravdin LD, Lockshin MD. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum 2006; 54:2515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/21\">",
"      Hanly JG, Robichaud J, Fisk JD. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J Rheumatol 2006; 33:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/22\">",
"      Steup-Beekman G, Steens S, van Buchem M, Huizinga T. Anti-NMDA receptor autoantibodies in patients with systemic lupus erythematosus and their first-degree relatives. Lupus 2007; 16:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/23\">",
"      Kimura A, Kanoh Y, Sakurai T, et al. Antibodies in patients with neuropsychiatric systemic lupus erythematosus. Neurology 2010; 74:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/24\">",
"      Galeazzi M, Annunziata P, Sebastiani GD, et al. Anti-ganglioside antibodies in a large cohort of European patients with systemic lupus erythematosus: clinical, serological, and HLA class II gene associations. European Concerted Action on the Immunogenetics of SLE. J Rheumatol 2000; 27:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/25\">",
"      Williams RC Jr, Sugiura K, Tan EM. Antibodies to microtubule-associated protein 2 in patients with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2004; 50:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/26\">",
"      Lefranc D, Launay D, Dubucquoi S, et al. Characterization of discriminant human brain antigenic targets in neuropsychiatric systemic lupus erythematosus using an immunoproteomic approach. Arthritis Rheum 2007; 56:3420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/27\">",
"      Kozora E, Ellison MC, West S. Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus. Arthritis Rheum 2004; 51:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/28\">",
"      Carbotte RM, Denburg SD, Denburg JA. Prevalence of cognitive impairment in systemic lupus erythematosus. J Nerv Ment Dis 1986; 174:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/29\">",
"      Rogers MP, Waterhouse E, Nagel JS, et al. I-123 iofetamine SPECT scan in systemic lupus erythematosus patients with cognitive and other minor neuropsychiatric symptoms: a pilot study. Lupus 1992; 1:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/30\">",
"      Holliday SL, Navarrete MG, Hermosillo-Romo D, et al. Validating a computerized neuropsychological test battery for mixed ethnic lupus patients. Lupus 2003; 12:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/31\">",
"      Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 1990; 33:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/32\">",
"      McLean BN, Miller D, Thompson EJ. Oligoclonal banding of IgG in CSF, blood-brain barrier function, and MRI findings in patients with sarcoidosis, systemic lupus erythematosus, and Beh&ccedil;et's disease involving the nervous system. J Neurol Neurosurg Psychiatry 1995; 58:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/33\">",
"      Okamoto H, Katsumata Y, Nishimura K, Kamatani N. Interferon-inducible protein 10/CXCL10 is increased in the cerebrospinal fluid of patients with central nervous system lupus. Arthritis Rheum 2004; 50:3731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/34\">",
"      George-Chandy A, Trysberg E, Eriksson K. Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms. Arthritis Res Ther 2008; 10:R97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/35\">",
"      Trysberg E, Nylen K, Rosengren LE, Tarkowski A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum 2003; 48:2881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/36\">",
"      Khoshbin, S, Levine, L, Milrod, L, et al. Cortical evoked potential mapping in complex partial seizures (abstract). Neurology 1984; 34:S219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/37\">",
"      Ritchlin CT, Chabot RJ, Alper K, et al. Quantitative electroencephalography. A new approach to the diagnosis of cerebral dysfunction in systemic lupus erythematosus. Arthritis Rheum 1992; 35:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/38\">",
"      Sibbitt WL Jr, Sibbitt RR, Brooks WM. Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1999; 42:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/39\">",
"      Jarek MJ, West SG, Baker MR, Rak KM. Magnetic resonance imaging in systemic lupus erythematosus patients without a history of neuropsychiatric lupus erythematosus. Arthritis Rheum 1994; 37:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/40\">",
"      Stimmler MM, Coletti PM, Quismorio FP Jr. Magnetic resonance imaging of the brain in neuropsychiatric systemic lupus erythematosus. Semin Arthritis Rheum 1993; 22:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/41\">",
"      Scott TF, Hess D, Brillman J. Antiphospholipid antibody syndrome mimicking multiple sclerosis clinically and by magnetic resonance imaging. Arch Intern Med 1994; 154:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/42\">",
"      Kozora E, West SG, Kotzin BL, et al. Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 1998; 41:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/43\">",
"      Taccari E, Sili Scavalli A, Spadaro A, et al. Magnetic resonance imaging (MRI) of the brain in SLE: ECLAM and SLEDAI correlations. Clin Exp Rheumatol 1994; 12:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/44\">",
"      Ishikawa O, Ohnishi K, Miyachi Y, Ishizaka H. Cerebral lesions in systemic lupus erythematosus detected by magnetic resonance imaging. Relationship to anticardiolipin antibody. J Rheumatol 1994; 21:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/45\">",
"      Sibbitt WL Jr, Brooks WM, Haseler LJ, et al. Spin-spin relaxation of brain tissues in systemic lupus erythematosus. A method for increasing the sensitivity of magnetic resonance imaging for neuropsychiatric lupus. Arthritis Rheum 1995; 38:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/46\">",
"      McCune WJ, MacGuire A, Aisen A, Gebarski S. Identification of brain lesions in neuropsychiatric systemic lupus erythematosus by magnetic resonance scanning. Arthritis Rheum 1988; 31:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/47\">",
"      Jacobs L, Kinkel PR, Costello PB, et al. Central nervous system lupus erythematosus: the value of magnetic resonance imaging. J Rheumatol 1988; 15:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/48\">",
"      Cauli A, Montaldo C, Peltz MT, et al. Abnormalities of magnetic resonance imaging of the central nervous system in patients with systemic lupus erythematosus correlate with disease severity. Clin Rheumatol 1994; 13:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/49\">",
"      Appenzeller S, Rondina JM, Li LM, et al. Cerebral and corpus callosum atrophy in systemic lupus erythematosus. Arthritis Rheum 2005; 52:2783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/50\">",
"      Rubbert A, Marienhagen J, Pirner K, et al. Single-photon-emission computed tomography analysis of cerebral blood flow in the evaluation of central nervous system involvement in patients with systemic lupus erythematosus. Arthritis Rheum 1993; 36:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/51\">",
"      Driver CB, Wallace DJ, Lee JC, et al. Clinical validation of the watershed sign as a marker for neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2008; 59:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/52\">",
"      Emmi L, Bramati M, De Cristofaro MT, et al. MRI and SPECT investigations of the CNS in SLE patients. Clin Exp Rheumatol 1993; 11:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/53\">",
"      Nossent JC, Hovestadt A, Sch&ouml;nfeld DH, Swaak AJ. Single-photon-emission computed tomography of the brain in the evaluation of cerebral lupus. Arthritis Rheum 1991; 34:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/54\">",
"      Waterloo K, Omdal R, Sj&ouml;holm H, et al. Neuropsychological dysfunction in systemic lupus erythematosus is not associated with changes in cerebral blood flow. J Neurol 2001; 248:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/55\">",
"      Govoni M, Castellino G, Padovan M, et al. Recent advances and future perspective in neuroimaging in neuropsychiatric systemic lupus erythematosus. Lupus 2004; 13:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/56\">",
"      Harris KG, Yuh WT. Intracranial vasculitis. Neuroimaging Clin N Am 1994; 4:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/57\">",
"      Griffey RH, Brown MS, Bankhurst AD, et al. Depletion of high-energy phosphates in the central nervous system of patients with systemic lupus erythematosus, as determined by phosphorus-31 nuclear magnetic resonance spectroscopy. Arthritis Rheum 1990; 33:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/58\">",
"      Sibbitt WL Jr, Haseler LJ, Griffey RH, et al. Analysis of cerebral structural changes in systemic lupus erythematosus by proton MR spectroscopy. AJNR Am J Neuroradiol 1994; 15:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/59\">",
"      Axford JS, Howe FA, Heron C, Griffiths JR. Sensitivity of quantitative (1)H magnetic resonance spectroscopy of the brain in detecting early neuronal damage in systemic lupus erythematosus. Ann Rheum Dis 2001; 60:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/60\">",
"      Pinching AJ, Travers RL, Hughes GR, et al. Oxygen-15 brain scanning for detection of cerebral involvement in systemic lupus erythematosus. Lancet 1978; 1:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/61\">",
"      Weiner SM, Otte A, Schumacher M, et al. Diagnosis and monitoring of central nervous system involvement in systemic lupus erythematosus: value of F-18 fluorodeoxyglucose PET. Ann Rheum Dis 2000; 59:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/62\">",
"      Steens SC, Admiraal-Behloul F, Bosma GP, et al. Selective gray matter damage in neuropsychiatric lupus. Arthritis Rheum 2004; 50:2877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/63\">",
"      Steens SC, Bosma GP, Steup-Beekman GM, et al. Association between microscopic brain damage as indicated by magnetization transfer imaging and anticardiolipin antibodies in neuropsychiatric lupus. Arthritis Res Ther 2006; 8:R38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5816/abstract/64\">",
"      Kumral E, Evyapan D, Keser G, et al. Detection of microembolic signals in patients with neuropsychiatric lupus erythematosus. Eur Neurol 2002; 47:131.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4865 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-188.40.116.55-6D8648E745-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_43_5816=[""].join("\n");
var outline_f5_43_5816=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SEROLOGIC STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PSYCHOLOGIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CEREBROSPINAL FLUID ANALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ELECTROENCEPHALOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      IMAGING STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CT scanning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Single photon emission computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/4865\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/4865|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/9/22687\" title=\"diagnostic image 1\">",
"      Lupus sclerosis MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/4865|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/40/18061\" title=\"table 1\">",
"      Sx neuropsychiatric lupus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/44/22220\" title=\"table 2\">",
"      Causes neuropsychiatric lupus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/35/34363\" title=\"table 3\">",
"      Dx neuropsychiatric lupus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27718?source=related_link\">",
"      Antiribosomal P protein antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/11/33978?source=related_link\">",
"      Neurologic manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38631?source=related_link\">",
"      Neuropsychiatric manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_43_5817="Rhythm control versus rate control in atrial fibrillation";
var content_f5_43_5817=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rhythm control versus rate control in atrial fibrillation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/43/5817/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/43/5817/contributors\">",
"     Kapil Kumar, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/43/5817/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/43/5817/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/43/5817/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/43/5817/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/43/5817/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/43/5817/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation (AF) is the most common sustained arrhythmia. It may cause significant symptoms and impair both functional status and quality of life. Without therapeutic intervention, affected patients are at increased risk for mortality (1.5- to 1.9-fold in the Framingham study) and morbidity (thromboembolic events and limiting symptoms).",
"   </p>",
"   <p>",
"    In AF, the loss of the regular and organized contraction of the left atrium as well as the subsequent increase in ventricular rate, lead to both immediate and long-term adverse consequences: deterioration in hemodynamics secondary to increased heart rate and loss of atrioventricular (AV) synchrony, an increased risk for stroke and other embolic events from left atrial thrombi, and progressive dysfunction of the left atrium and left ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=see_link\">",
"     \"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link\">",
"     \"Tachycardia-mediated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For each patient with AF, the two principal goals of therapy are symptom control and the prevention of thromboembolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=see_link&amp;anchor=H2#H2\">",
"     \"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm\", section on 'Adverse hemodynamics in AF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rate- and rhythm-control strategies improve symptoms, but neither has been conclusively shown to improve survival compared to the other. (See",
"    <a class=\"local\" href=\"#H5421069\">",
"     'Definitions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For each patient with AF, a decision should be made as to which approach will be used for long-term management. The following points should be kept in mind irrespective of strategy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Both strategies can fail both in the short and long terms. As a consequence many patients need to be reconsidered for the alternate strategy as the natural history of their disease progresses.",
"     </li>",
"     <li>",
"      All patients with AF, irrespective of strategy",
"      <span class=\"nowrap\">",
"       chosen/rhythm,",
"      </span>",
"      should have their thromboembolic risk assessed and be managed accordingly. (See",
"      <a class=\"local\" href=\"#H5421857\">",
"       'Thromboembolic risk'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For patients who are managed with a rhythm-control strategy, rate control is necessary due to the possibility of the return of AF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The advantages and disadvantages of rhythm and rate control, as well as whether there are subgroups of patients in whom one or the other should be preferred, will be discussed here. The methods to achieve rhythm or rate control are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5421657\">",
"    <span class=\"h2\">",
"     Patients with recent onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who present with recent onset AF, relatively rapid decisions, including the choice between rhythm and rate control, often need to be made. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=see_link\">",
"     \"Management of new onset atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5421069\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rhythm-control strategy uses antiarrhythmic drug therapy, radiofrequency catheter ablation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a surgical procedure performed at the time of open heart surgery to maintain sinus rhythm. Many patients who remain in sinus rhythm require rate slowing drugs (in the event of return to AF) long term as well as antithrombotic therapy. (See",
"    <a class=\"local\" href=\"#H5421857\">",
"     'Thromboembolic risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A rate-control strategy uses drugs that block (slow conduction through) the atrioventricular (AV) node such as beta blockers, rate-slowing calcium channel blockers, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    . Atrioventricular (AV) nodal ablation plus ventricular pacing to control symptoms is also used when drug therapy is ineffective. Rate control goals are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link&amp;anchor=H4#H4\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\", section on 'Rate control goals'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5421857\">",
"    <span class=\"h1\">",
"     THROMBOEMBOLIC RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thromboembolism is the most important adverse outcome of AF. Unfortunately, maintaining sinus rhythm does not reduce the frequency of clinical thromboembolization. The AFFIRM and RACE trials demonstrated that embolic events occurred with equal frequency regardless of whether a rate control or rhythm-control strategy was pursued; furthermore, most embolic events (113 of 157 ischemic strokes in AFFIRM and 29 of 35 embolic events in RACE) occurred after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    had been stopped or when the International Normalized Ratio (INR) was subtherapeutic (less than 2.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. These findings indicate that high-risk patients in whom a rhythm-control strategy is pursued still require chronic anticoagulation, even if it seems that sinus rhythm is maintained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are at least three explanations for the failure of rhythm control to reduce embolic risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite successful cardioversion and antiarrhythmic drug therapy, the recurrence rate of either intermittent (paroxysmal) or persistent (chronic) AF is 35 to 60 percent at one year with intermittent monitoring (",
"      <a class=\"graphic graphic_figure graphicRef69285 \" href=\"UTD.htm?4/48/4878\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/5,6\">",
"       5,6",
"      </a>",
"      ] and up to 88 percent with continuous monitoring (permanent pacemaker with AF detection function and electrogram storage) for more than 18 months [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/7\">",
"       7",
"      </a>",
"      ]. In the AFFIRM trial described below, there was a high crossover rate from rhythm to rate control (17 and 38 percent of patients at one and five years), due primarily to inability to maintain sinus rhythm and drug intolerance [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/3\">",
"       3",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Up to 90 percent of recurrences are asymptomatic [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/8\">",
"       8",
"      </a>",
"      ] and asymptomatic episodes lasting more than 48 hours are not uncommon, occurring in 17 percent of patients in a report using continuous monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/7\">",
"       7",
"      </a>",
"      ]. During these prolonged episodes of AF, thrombi can form that may cause clinical thromboembolism. The continuous monitoring study also showed that 40 percent of patients had episodes of AF-like symptoms in the absence of AF [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/7\">",
"       7",
"      </a>",
"      ]. Even very brief episodes of AF can increase stroke risk. In a study using pacemakers for arrhythmia detection in patients without a history of AF, AF duration for greater than five minutes increased the risk of thromboembolic events sixfold compared to patients with similar or greater CHADS2 score and no detected AF [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with nonvalvular AF that is not due to a reversible disease (eg, hyperthyroidism, cardiac surgery) often have other predisposing factors for embolism even when they are in sinus rhythm. These include complex aortic plaque and left ventricular systolic dysfunction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=see_link\">",
"       \"Indications for antithrombotic therapy in heart failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10809?source=see_link\">",
"       \"Embolism from aortic plaque: Thromboembolism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There may be atrial heterogeneity with the surface electrocardiogram and body of the left atrium demonstrating sinus mechanism while the atrial appendage displays an AF contraction pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thus, the implementation of either strategy requires the assessment of the need for antithrombotic therapy. Issues related to risk stratification and the approach to antithrombotic therapy in patients with AF are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=see_link\">",
"       \"Risk of embolization in atrial fibrillation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A separate issue from chronic antithrombotic therapy is anticoagulation related to cardioversion. The recommended approach to such patients is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     COMPARATIVE STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least seven randomized trials have compared rate and rhythm control approaches in the broad population of patients with AF and demonstrated equivalent outcomes (such as the rates of death or embolism) in both arms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/3,4,11-13\">",
"     3,4,11-13",
"    </a>",
"    ]. Two large trials, AFFIRM and RACE, will be discussed in detail. One trial demonstrated improved quality of life scores with rhythm control [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/14\">",
"     14",
"    </a>",
"    ]. A large, 2012 observational study, found a lower risk of death at both five and eight years of follow-up with rhythm control [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     AFFIRM trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;AFFIRM, the largest trial, randomly assigned 4060 patients with recurrent AF to rate control (using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , beta blocker,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    calcium channel blocker) and anticoagulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or to rhythm control with the most effective antiarrhythmic drug, with the use of warfarin left up to the discretion of the investigator [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients had to be at least 65 years of age (mean age 70) or have other risk factors for stroke or death and there could be no contraindications to antiarrhythmic or anticoagulation therapy. All patients were initially anticoagulated, but those in the rhythm control arm who maintained sinus rhythm could be withdrawn from warfarin.",
"   </p>",
"   <p>",
"    In the rate control arm of the study, the goals were a ventricular rate of 80 beats per min at rest and 110 beats per minute during a six-minute walk test. At five years, 35 percent of patients were in sinus rhythm (compared to 63 percent with rhythm control), while over 80 percent of those still in AF had \"adequate heart rate control.\" Over 85 percent of patients in the rate control arm were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . Radiofrequency ablation of the atrioventricular node was required in 105 patients (5 percent) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the rhythm control arm of the study, sinus rhythm was maintained in 82 and 63 percent of patients at one and five years; only 1 percent underwent nonpharmacologic therapy to maintain rhythm control. The most frequently used initial antiarrhythmic drugs were",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    (38 percent) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    (31 percent). By the end of 3.5 years of follow-up, 63 percent of patients had had at least one trial of amiodarone.",
"   </p>",
"   <p>",
"    Among patients initially assigned to rhythm control, crossover to rate control occurred in 17 and 38 percent of patients at one and five years, primarily due to inability to maintain sinus rhythm and drug intolerance. In those originally assigned to rate control, the crossover rate to rhythm control was lower at 8 and 15 percent, primarily due to failure to control symptoms due to AF and heart failure.",
"   </p>",
"   <p>",
"    After a mean follow-up of 3.5 years, the following findings were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was an almost significant trend toward a decrease in the rate of occurrence of the primary endpoint (all-cause mortality) with rate control (21.3 versus 23.8 percent, hazard ratio [HR] 0.87, 95% CI 0.75-1.01) (",
"      <a class=\"graphic graphic_figure graphicRef61608 \" href=\"UTD.htm?19/25/19870\">",
"       figure 2",
"      </a>",
"      ). There was no difference between the two groups in the incidence of cardiac death, arrhythmic death, or deaths due to ischemic or hemorrhagic stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/16\">",
"       16",
"      </a>",
"      ]. Two prespecified subgroups had a significant reduction in mortality with rate control: those without a history of heart failure (adjusted HR 0.69) and those aged 65 years or older (HR 0.76) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There was no significant difference in the composite secondary endpoint of death, ischemic stroke, anoxic encephalopathy, major bleeding, or cardiac arrest.",
"     </li>",
"     <li>",
"      There was no significant difference in global functional status or quality of life in the initial report.",
"     </li>",
"     <li>",
"      The number of patients requiring hospitalization during follow-up was significantly lower in the rate control group than in the rhythm control group (73 versus 80 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent report provided evidence that the trend toward increased mortality with rhythm control was due to the deleterious effects of antiarrhythmic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/18\">",
"     18",
"    </a>",
"    ]. In this analysis, the use of antiarrhythmic drugs was associated with a significant increase in mortality (hazard ratio 1.49), while the presence of sinus rhythm was associated with a significant reduction in mortality (hazard ratio 0.53). It could not be determined if the latter effect was due to sinus rhythm itself or to AF being a marker for a confounding factor or factors that affect survival, such as heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     RACE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RACE trial enrolled 522 patients (mean age 68) with recurrent persistent AF or atrial flutter less than one year in duration who had required one to two cardioversions within the prior two years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of atrial fibrillation\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients were randomly assigned to rate control using the same AV nodal blocking drugs as used in AFFIRM or to rhythm control. Successful rate control was defined as a ventricular rate below 100",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    and no symptoms. Initial therapy for rhythm control was",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    . If AF recurred within six months, antiarrhythmic drug therapy was changed; if AF again recurred within six months,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    was substituted. A late recurrence, after more than six months of therapy, was treated with repeat cardioversion and continuation of the same antiarrhythmic agent.",
"   </p>",
"   <p>",
"    The primary endpoint was a composite of cardiovascular death, admission for heart failure, thromboembolic event, severe bleeding, pacemaker implantation, or severe side effects from antiarrhythmic drugs. After a mean 2.3-year follow-up, the following findings were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significantly fewer patients were in sinus rhythm in the rate control group (10 versus 39 percent).",
"     </li>",
"     <li>",
"      There was an almost significant trend toward a lower incidence of the primary endpoint with rate control (17.2 versus 22.6 percent with rhythm control, hazard ratio 0.73, 90% CI 0.53-1.01) (",
"      <a class=\"graphic graphic_figure graphicRef74434 \" href=\"UTD.htm?8/51/9022\">",
"       figure 3",
"      </a>",
"      ). There was no difference in cardiovascular mortality (6.8 versus 7 percent). However, there was a trend toward a higher incidence of nonfatal endpoints among patients assigned to rhythm control, including heart failure, thromboembolism, pacemaker insertion, and adverse drug reactions.",
"     </li>",
"     <li>",
"      There were no significant differences in quality of life between the rate and rhythm control groups, a finding similar to that in AFFIRM [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/20\">",
"       20",
"      </a>",
"      ]. Improvement in quality of life was associated with symptomatic AF at baseline, a short duration of AF, and the presence of sinus rhythm at the end of follow-up, rather than the assigned strategy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It has been thought that restoration and maintenance of sinus rhythm may be of particular importance in patients with cardiomyopathy and symptomatic heart failure who have AF, based upon the expectation that hemodynamics would improve and heart failure would be more easily controlled in such patients if they were in sinus rhythm. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link&amp;anchor=H7#H7\">",
"     \"Atrial fibrillation in patients with heart failure\", section on 'Rhythm versus rate control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5420861\">",
"    <span class=\"h2\">",
"     Limitations of trial data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limitations of the RACE and AFFIRM trials should be kept in mind:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean age in AFFIRM and RACE was 70 and 68 years, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. It is therefore uncertain if younger healthy patients might benefit from more aggressive rhythm control [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/21,22\">",
"       21,22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Approximately one-half of patients in AFFIRM who had a detailed history had symptomatic episodes of AF that occurred less often than once per month [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/23\">",
"       23",
"      </a>",
"      ]. Such patients would be expected to derive little symptomatic benefit from rhythm control, and the results may not directly apply to patients with frequent episodes of symptomatic AF [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The use of antiarrhythmic drugs in AFFIRM was associated with a significant increase in mortality (hazard ratio 1.49), which was due to non-cardiovascular causes, while the presence of sinus rhythm was associated with a significant reduction in mortality (hazard ratio 0.53) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/16,18\">",
"       16,18",
"      </a>",
"      ]. A similar benefit from being in sinus rhythm (relative risk 0.44) was noted in the DIAMOND trial that compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       dofetilide",
"      </a>",
"      to placebo in patients with reduced left ventricular systolic function [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link\">",
"       \"Atrial fibrillation in patients with heart failure\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      One interpretation of these data is that maintenance of sinus rhythm might be beneficial if there were a safer and more effective approach than current antiarrhythmic drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/19,25\">",
"       19,25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link&amp;anchor=H29#H29\">",
"       \"Overview of atrial fibrillation\", section on 'Long-term outcome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The AFFIRM and RACE data were largely gathered before catheter ablation was common. The potential impact of this procedure (versus chronic antiarrhythmic therapy) remains incompletely explored. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"       \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Both trials allowed for cessation of anticoagulant therapy four weeks after documentation of sinus rhythm, leading to a higher rate of stroke. It has been postulated that continued anticoagulation might have led to a lower mortality in the rhythm control group [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21587202\">",
"    <span class=\"h2\">",
"     Canadian health care database study",
"    </span>",
"    &nbsp;&mdash;&nbsp;One additional caveat to the list of caveats (presented above) about the RACE and AFFIRM trials is that, while randomized trials are generally the best study design to compare outcomes with two or more differing interventions, the generalizability of their results to &ldquo;real world&rdquo; populations can be questioned. For example, risk profiles and adherence to therapy may differ between those enrolled in randomized trials and those in large observational studies.",
"   </p>",
"   <p>",
"    Using a population-based database from Quebec, Canada, a 2012 observational study evaluated the comparative effectiveness in reducing mortality between a rhythm or a rate control strategy in 26,130 patients 66 years or older who were hospitalized with AF [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/15\">",
"     15",
"    </a>",
"    ]. These individuals had not received rate or rhythm control drugs in the year before hospitalization and received a prescription within seven days of discharge. After a mean follow-up of 3.1 years, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Death occurred in 49.5 percent of the entire cohort (the mean age at baseline was 79 years).",
"     </li>",
"     <li>",
"      Antiarrhythmic medication was prescribed in 24.5 percent.",
"     </li>",
"     <li>",
"      During the first six months, there was a small increase in the risk of death for patients treated with rhythm control (hazard ratio [HR] 1.07, 95% CI 1.01-1.14).",
"     </li>",
"     <li>",
"      Mortality was similar between the two groups until year four. However, the relative risk of death, comparing rhythm to rate control, fell thereafter and the risk was lower at five and eight years (HR 0.89, 95% CI 0.81-0.96 and 0.77, 95% CI 0.62-0.95, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CHOICE OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data from the clinical trials suggest that both rate and rhythm control are acceptable approaches, with comparable rates of mortality and stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/11,12,20\">",
"     11,12,20",
"    </a>",
"    ]. As discussed below, we prefer a rate-control strategy in most patients.",
"   </p>",
"   <p>",
"    However, an individual patient may do better with one or the other, and in many cases only after trying one strategy is utility known. When choosing a strategy, the major factors that should be considered are the relative ability of each strategy to control symptoms and the relative burdens imposed by each.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Preference for rate control",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients with AF, particularly recurrent AF, we prefer rate control as the initial approach [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/19,21,22,27\">",
"     19,21,22,27",
"    </a>",
"    ]. This is based upon the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The results from AFFIRM and RACE show equivalent and perhaps better outcomes with rate control (",
"      <a class=\"graphic graphic_figure graphicRef61608 \" href=\"UTD.htm?19/25/19870\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef74434 \" href=\"UTD.htm?8/51/9022\">",
"       figure 3",
"      </a>",
"      ) as well as a similar requirement for anticoagulation [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. A meta-analysis of above five trials, in which AFFIRM accounted for 77 percent of the patients, found a strong trend toward a reduction in all-cause mortality with rate control (13.0 versus 14.6 percent with rhythm control, odds ratio 0.87, 95% CI 0.74-1.02) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/28\">",
"       28",
"      </a>",
"      ]. The proportion of patients who had an ischemic stroke was similar with the two approaches (3.5 versus 3.9 percent).",
"     </li>",
"     <li>",
"      Important side effects, especially proarrhythmia, are associated with antiarrhythmic drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/18,29-31\">",
"       18,29-31",
"      </a>",
"      ]. In addition pulmonary vein isolation using radiofrequency catheter ablation is associated with important complications. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link&amp;anchor=H39#H39\">",
"       \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\", section on 'Complications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is an appreciable rate of recurrent AF and frequent crossover to a rate-control strategy when antiarrhythmic drugs are used for maintenance therapy after conversion to sinus rhythm. Recurrence is detected clinically in 20 to 60 percent at one year (",
"      <a class=\"graphic graphic_figure graphicRef69285 \" href=\"UTD.htm?4/48/4878\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/32\">",
"       32",
"      </a>",
"      ]. Furthermore, a continuous monitoring study found that recurrent episodes occurred in approximately 90 percent of patients; many of these episodes were asymptomatic, including some lasting more than 48 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/7\">",
"       7",
"      </a>",
"      ]. The risk of recurrent AF is highest in the patient who has hypertension, an enlarged left atrium, AF for more than one year, or heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rate control is generally preferred in patients with heart failure. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=see_link&amp;anchor=H7#H7\">",
"     \"Atrial fibrillation in patients with heart failure\", section on 'Rhythm versus rate control'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5422443\">",
"    <span class=\"h3\">",
"     Newly detected AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the American Academy of Family",
"    <span class=\"nowrap\">",
"     Practice/American",
"    </span>",
"    College of Physicians guideline recommendation that maintenance antiarrhythmic drug therapy",
"    <strong>",
"     not",
"    </strong>",
"    be routinely used after cardioversion in patients with their first presentation with AF [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/21,27\">",
"     21,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=see_link&amp;anchor=H521214080#H521214080\">",
"     \"Management of new onset atrial fibrillation\", section on 'Antiarrhythmic therapy after reversion to sinus rhythm'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5422494\">",
"    <span class=\"h3\">",
"     Very elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients over age 80 account for approximately 35 percent of patients with AF and the prevalence of AF is about 10 percent (",
"    <a class=\"graphic graphic_figure graphicRef77268 \" href=\"UTD.htm?2/14/2286\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. These individuals are underrepresented in clinical trials. Rhythm control is less often preferred in such patients for the following reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      They are more sensitive to the proarrhythmic effects of drugs",
"     </li>",
"     <li>",
"      AF is often permanent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Preference for rhythm control",
"    </span>",
"    &nbsp;&mdash;&nbsp;While it seems intuitive that an individual patient would feel better in sinus rhythm than in AF (even with rate control) not all such patients feel better. Demonstrating that sinus rhythm improves symptoms and quality of life has been difficult for two reasons, related in large part by limitations of antiarrhythmic drug therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limited efficacy: a substantial percentage of patients in whom a rhythm-control strategy is chosen continue to have AF.",
"     </li>",
"     <li>",
"      Side effects: proarrhythmia, and inconveniences (eg, monitoring tests and dose adjustments), that have a negative impact on quality of life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients in whom sinus rhythm is successfully maintained, exercise capacity and quality of life are improved [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Thus, many experts see the failure to demonstrate improved outcomes with rhythm-control strategies as a reflection of the inadequacies of available therapies, rather than a clinical equivalence between AF with rate control and sinus rhythm.",
"   </p>",
"   <p>",
"    Despite the general preference for a rate-control strategy, and the difficulty in demonstrating improved outcomes with rhythm control, there are several situations in which rhythm control is preferable [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Failure of rate control",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two manifestations of failure of rate control:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent symptoms (palpitations, dyspnea, lightheadedness, angina, and near syncope) despite adequate rate control. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=see_link\">",
"       \"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An inability to attain adequate rate control as defined above. In these patients, alternatives to rhythm control with antiarrhythmic drug therapy include radiofrequency ablation of the AV node with pacemaker insertion or radiofrequency catheter ablation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=see_link\">",
"       \"Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"       \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5422894\">",
"    <span class=\"h3\">",
"     Younger patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Younger individuals, or those who need to carry out activities requiring optimal cardiac performance, generally do not tolerate AF well. When antiarrhythmic drugs are used in this setting, patients should be well informed of the benefits and risks of this therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Patients early in their natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence that suggests it is easier to maintain sinus rhythm earlier in the natural history of AF than later [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/38\">",
"     38",
"    </a>",
"    ]. Therefore, patients for whom a rhythm-control strategy is chosen should have AF restored to sinus rhythm early once adequate thromboembolic prophylaxis has been achieved.",
"   </p>",
"   <p>",
"    We consider cardioversion to sinus rhythm in most patients (particularly younger patients) with a first episode of AF in whom the arrhythmia is of recent onset and the risk for recurrence appears to be low based upon the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      LA size less than 4.5 to 5 cm",
"     </li>",
"     <li>",
"      A reversible underlying disorder such as hyperthyroidism, pericarditis, pulmonary embolism, or cardiac surgery",
"     </li>",
"     <li>",
"      No hypertension or hypertensive heart disease",
"     </li>",
"     <li>",
"      Normal left ventricular systolic function or absence of heart failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cardioversion should only be attempted when the risk of embolization has been lowered to an acceptable level. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5421322\">",
"    <span class=\"h2\">",
"     Recommendations of others",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 European Society of Cardiology guidelines for the management of AF make the following recommendations for choosing between rhythm- or rate-control strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rate control is strongly preferred as the initial approach in elderly patients with minor symptoms.",
"     </li>",
"     <li>",
"      Rhythm control is strongly preferred in patients with symptoms despite rate control, including those with persistent symptoms of heart failure.",
"     </li>",
"     <li>",
"      Rhythm control is weakly preferred as an initial approach in young symptomatic patients.",
"     </li>",
"     <li>",
"      Rhythm controls is weakly preferred in patients with AF secondary to a trigger or substrate that has been corrected.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology guideline did not make specific recommendations regarding rhythm versus rate control, nor did the 2010 focused update [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5817/abstract/29,39\">",
"     29,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"       \"Patient information: Atrial fibrillation (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5421057\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For each patient with atrial fibrillation (AF), the two principal goals of therapy are symptom control and the prevention of thromboembolism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=see_link&amp;anchor=H2#H2\">",
"       \"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm\", section on 'Adverse hemodynamics in AF'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rhythm- and rate-control strategies are associated with similar rates of mortality and serious morbidity, such as embolic risk, which is best addressed using anticoagulation based on the CHADS2 criteria. (See",
"      <a class=\"local\" href=\"#H5421857\">",
"       'Thromboembolic risk'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In addition, assessments of quality of life have not shown significant differences between the two in most studies. (See",
"      <a class=\"local\" href=\"#H5421069\">",
"       'Definitions'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      A rate-control strategy generally uses drugs that block the atrioventricular (AV) node, such as beta blockers, rate-slowing calcium channel blockers, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      . AV nodal ablation plus ventricular pacing is another option.",
"     </li>",
"     <li>",
"      Patients managed by either rate or rhythm control must be assessed for their thromboembolic risk. Therapy should be initiated when appropriate. (See",
"      <a class=\"local\" href=\"#H5421857\">",
"       'Thromboembolic risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rhythm- and rate-control strategies are associated with similar rates of mortality and serious morbidity, such as embolic risk. In addition, assessments of quality of life have not shown significant differences between the two in most studies. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Comparative studies'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The principal reasons to prefer a rate-control strategy include simplification of the medical regimen, lower cost, and less concern about the risks of antiarrhythmic drug therapy (such as torsades de pointes) or radiofrequency catheter ablation. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Preference for rate control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For asymptomatic or mildly symptomatic AF patients who are 65 years or older, we suggest a rate-control as opposed to a rhythm-control strategy using medical therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This recommendation places a high priority on concerns about side effects of antiarrhythmic drug therapy or radiofrequency catheter ablation. Patients for whom a rhythm-control strategy may be reasonable include those who continue with clinically significant symptoms on a rate-control strategy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Preference for rate control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with AF younger than age 65, particularly those who are symptomatic, we suggest a rhythm control as opposed to a rate-control strategy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This recommendation places a high priority on relief of symptoms as well as the potential, but as yet unproven benefit, from remaining in sinus rhythm over long periods of time. For younger, asymptomatic patients who are concerned about the potential side effects of antiarrhythmic drug therapy, and who are not inclined to undergo radiofrequency catheter ablation, a rate-control strategy is reasonable. In these patients an informed discussion of the benefits and risks of antiarrhythmic drug therapy is critically important. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Preference for rhythm control'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/1\">",
"      Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/2\">",
"      Chugh SS, Blackshear JL, Shen WK, et al. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001; 37:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/3\">",
"      Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/4\">",
"      Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/5\">",
"      Zarembski DG, Nolan PE Jr, Slack MK, Caruso AC. Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide. Arch Intern Med 1995; 155:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/6\">",
"      Antonielli E, Pizzuti A, P&aacute;link&aacute;s A, et al. Clinical value of left atrial appendage flow for prediction of long-term sinus rhythm maintenance in patients with nonvalvular atrial fibrillation. J Am Coll Cardiol 2002; 39:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/7\">",
"      Israel CW, Gr&ouml;nefeld G, Ehrlich JR, et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 2004; 43:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/8\">",
"      Page RL, Wilkinson WE, Clair WK, et al. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994; 89:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/9\">",
"      Botto GL, Padeletti L, Santini M, et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol 2009; 20:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/10\">",
"      Seto TB, Buchholz WA, Douglas PS, Manning WJ. When the body and appendage of the left atrium disagree: \"Focal\" atrial fibrillation-implications for atrial thrombus formation and risk of thromboembolism. J Am Soc Echocardiogr 1999; 12:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/11\">",
"      Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/12\">",
"      Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 2003; 41:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/13\">",
"      Opolski G, Torbicki A, Kosior DA, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004; 126:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/14\">",
"      Ogawa S, Yamashita T, Yamazaki T, et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM Study. Circ J 2009; 73:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/15\">",
"      Ionescu-Ittu R, Abrahamowicz M, Jackevicius CA, et al. Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation. Arch Intern Med 2012; 172:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/16\">",
"      Steinberg JS, Sadaniantz A, Kron J, et al. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004; 109:1973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/17\">",
"      Curtis AB, Gersh BJ, Corley SD, et al. Clinical factors that influence response to treatment strategies in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005; 149:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/18\">",
"      Corley SD, Epstein AE, DiMarco JP, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004; 109:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/19\">",
"      Bahnson TD, Grant AO. To be or not to be in normal sinus rhythm: what do we really know? Ann Intern Med 2004; 141:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/20\">",
"      Hagens VE, Ranchor AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol 2004; 43:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/21\">",
"      Snow V, Weiss KB, LeFevre M, et al. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2003; 139:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/22\">",
"      Zimetbaum P, Josephson ME. Is there a role for maintaining sinus rhythm in patients with atrial fibrillation? Ann Intern Med 2004; 141:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/23\">",
"      AFFIRM Investigators. Atrial Fibrillation Follow-up Investigation of Rhythm Management. Baseline characteristics of patients with atrial fibrillation: the AFFIRM Study. Am Heart J 2002; 143:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/24\">",
"      Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001; 104:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/25\">",
"      Waldo AL. A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: there remains an unmet need. Am Heart J 2006; 151:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/26\">",
"      Dewland TA, Marcus GM. Rate vs rhythm control in atrial fibrillation: can observational data trump randomized trial results? Arch Intern Med 2012; 172:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/27\">",
"      McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 2003; 139:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/28\">",
"      de Denus S, Sanoski CA, Carlsson J, et al. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med 2005; 165:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/29\">",
"      Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006; 48:e149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/30\">",
"      Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990; 82:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/31\">",
"      Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 1992; 20:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/32\">",
"      Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000; 342:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/33\">",
"      Dittrich HC, Erickson JS, Schneiderman T, et al. Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am J Cardiol 1989; 63:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/34\">",
"      Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285:2370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/35\">",
"      European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/36\">",
"      Chung MK, Shemanski L, Sherman DG, et al. Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy. J Am Coll Cardiol 2005; 46:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/37\">",
"      Singh SN, Tang XC, Singh BN, et al. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy. J Am Coll Cardiol 2006; 48:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/38\">",
"      Cosio FG, Aliot E, Botto GL, et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. Europace 2008; 10:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5817/abstract/39\">",
"      Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123:104.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1045 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-197.136.42.3-430C2FE721-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_43_5817=[""].join("\n");
var outline_f5_43_5817=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5421057\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5421657\">",
"      Patients with recent onset",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5421069\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5421857\">",
"      THROMBOEMBOLIC RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      COMPARATIVE STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      AFFIRM trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RACE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5420861\">",
"      Limitations of trial data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21587202\">",
"      Canadian health care database study",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CHOICE OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Preference for rate control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5422443\">",
"      - Newly detected AF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5422494\">",
"      - Very elderly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Preference for rhythm control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Failure of rate control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5422894\">",
"      - Younger patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Patients early in their natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5421322\">",
"      Recommendations of others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5421057\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1045\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1045|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/48/4878\" title=\"figure 1\">",
"      Recurrent AF after amiodarone propafenone and sotalol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/25/19870\" title=\"figure 2\">",
"      Rhythm versus rate control AF AFFIRM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/51/9022\" title=\"figure 3\">",
"      Rhythm versus rate control AF RACE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/14/2286\" title=\"figure 4\">",
"      Prevalence of atrial fibrillation with age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24408?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10809?source=related_link\">",
"      Embolism from aortic plaque: Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=related_link\">",
"      Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=related_link\">",
"      Indications for antithrombotic therapy in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/6/39016?source=related_link\">",
"      Management of new onset atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=related_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=related_link\">",
"      Risk of embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_43_5818="Diagnosis and management of asthma in older adults";
var content_f5_43_5818=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and management of asthma in older adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/43/5818/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/43/5818/contributors\">",
"     Paul L Enright, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/43/5818/contributors\">",
"     R Graham Barr, MD, DrPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/43/5818/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/43/5818/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/43/5818/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/43/5818/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/43/5818/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/43/5818/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asthma is common in adults over age 65 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It substantially reduces both psychological and physical quality of life among older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Some experts distinguish two categories of asthma in older adults. The first category comprises older patients whose typical symptoms of asthma developed in childhood or early adulthood and persisted through later life. Normal lung function is usually interspersed with intermittent periods of airflow obstruction. The second category comprises patients who first develop new symptoms of asthma as older adults. In these patients, the diagnosis may be challenging due to the higher incidence of COPD and the longer list of differential diagnoses.",
"   </p>",
"   <p>",
"    We find these two categories helpful for the discussion of the disease, but acknowledge their limitations. The clinical course may be more complex: for example, childhood asthma usually remits in adolescence, but often reappears later in adulthood. Evidence is lacking for the definition of these categories and for treatment strategies based upon these categories.",
"   </p>",
"   <p>",
"    Differentiation of asthma from chronic obstructive pulmonary disease (COPD) is important because the approach to treatment of asthma is different from that of COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/6\">",
"     6",
"    </a>",
"    ]. The frequent overlap of these two disorders in clinical practice also makes the distinction challenging in some cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of asthma in adults age 65 and older is about 4 to 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/1,2,7\">",
"     1,2,7",
"    </a>",
"    ]. Older adults report the onset of their asthma relatively equally over all decades of life [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/8\">",
"     8",
"    </a>",
"    ], but adult onset asthma is more likely to become life-long when compared to asthma beginning in childhood.",
"   </p>",
"   <p>",
"    Although hospitalization rates for elders with asthma generally declined during the last two decades, a prospective cohort study in 15 managed care organizations in the United States reported that older patients with asthma were twice as likely as young adults with asthma to be hospitalized during one year of follow-up (14 versus 7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/9\">",
"     9",
"    </a>",
"    ]. In contrast, The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study reported that the hospitalization rate was actually lower among the cohort age 65 and older than the younger cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    About 3,000 older people die of asthma each year in the United States. The increase in asthma mortality rates between 1979 and 1996 occurred primarily among people over age 65, with the highest increases seen among older black women [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/11\">",
"     11",
"    </a>",
"    ]. An Italian study of 210 community dwelling elderly patients with asthma compared with 1023 ambulatory older adults with nonrespiratory conditions found an increase in five year mortality among the asthma group (24.3 versus 16.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Atopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the prevalence of atopic symptoms, IgE levels, and positive allergen skin tests declines from childhood to older age [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/13\">",
"     13",
"    </a>",
"    ], about one-fourth of older adults have at least one positive allergen skin test and about three-fourths of older patients with asthma are allergic to one or more common indoor allergens (eg, cockroach, cat, dog, mites) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/5,14\">",
"     5,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older, as well as younger, adults with high levels of total IgE or specific IgE to cat or mite antigen (but not timothy grass or birch) are more likely to have bronchial hyperresponsiveness (BHR) or to develop BHR during two to three years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Older patients with asthma who have become sensitized to cockroach have more severe asthma and may experience a faster subsequent decline in lung function [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In Sweden and Finland, indoor dampness and mold growth are risk factors for adult-onset asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Irritant exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Irritant exposures also increase the risk of asthma. Up to half of older people with asthma are current or former smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/2\">",
"     2",
"    </a>",
"    ]. Cigarette smoking increases production of IgE antibodies, bronchial responsiveness, production of inflammatory markers in the sputum, and hyperinflation in older asthmatics [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/21\">",
"     21",
"    </a>",
"    ]. Exposure to environmental tobacco smoke, wood burning stoves, and cooking smoke from indoor use of biomass fuels (eg, wood, agricultural waste) is associated with the development of asthma in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/19,22,23\">",
"     19,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    About one-fourth of the asthma in adults is caused by workplace exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Asthma in older women living in Northern California is associated with occupations in art, decorating, photography, technology, health professions, food preparation, cleaning, social work, and service work [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/26\">",
"     26",
"    </a>",
"    ]. Exposure to dusts, gas, vapors, fumes, or sensitizers are also associated with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increases in outdoor air pollution, especially particulate matter, have been associated with asthma exacerbations and increased hospital admissions for respiratory disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/27-34\">",
"     27-34",
"    </a>",
"    ]. In a study of the respiratory effects of air pollution in older adults, daily hospital admissions for asthma were highly associated with increases in NO",
"    <sub>",
"     2",
"    </sub>",
"    and SO",
"    <sub>",
"     2",
"    </sub>",
"    in the cool seasons and increases in black smoke year around [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/35\">",
"     35",
"    </a>",
"    ]. Ozone levels may also contribute to the development of asthma in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Potential risk factors and triggers for asthma in older adults are similar to asthma triggers in other age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/8,22,36-40\">",
"     8,22,36-40",
"    </a>",
"    ]. A questionnaire has been developed by the NAEPP to help clinicians assess the relationship between exposure to triggers and asthma symptoms (",
"    <a class=\"graphic graphic_table graphicRef80507 \" href=\"UTD.htm?34/33/35357\">",
"     table 1",
"    </a>",
"    ). It is worthwhile to ask older patients with asthma about triggers, because more than one-third of older patients with asthma report exercise-induced asthma symptoms; half report that animal contacts, or exposure to dusts or fumes trigger their respiratory symptoms; and over two-thirds report seasonal worsening [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/2,41\">",
"     2,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Comorbid conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognized and unrecognized comorbid conditions are much more likely in older patients with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/42\">",
"     42",
"    </a>",
"    ]. The most worrisome common comorbidity is cardiovascular disease, specifically coronary heart disease (CHD), with its attendant risk of lethal arrhythmias.",
"   </p>",
"   <p>",
"    Obesity has been suggested as a risk factor for asthma in older women [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Obesity also appears to predict asthma among men, although the magnitude of the relationship may not be as strong.",
"   </p>",
"   <p>",
"    The incidence of adult-onset asthma drops with menopause but was elevated two-fold among women taking postmenopausal hormones (estrogen only and estrogen plus progestin) compared to women not taking postmenopausal hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/45-47\">",
"     45-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Comorbid conditions, like hypertension, coronary heart disease and glaucoma, may be treated with medications (eg, topical or systemic beta blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , or NSAIDs) that can exacerbate underlying asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Discontinuing the medication may lead to improved asthma control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The asthma symptoms of intermittent wheeze, cough, and chest tightness are no different in older persons than in younger persons, but older individuals are more likely to be poor perceivers of dyspnea related to airway obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Elder patients may have moderate to severe airway obstruction yet may not complain of dyspnea occurring with reported attacks of wheezing, chest tightness, or cough. This may be the result of adaptation to the long term presence of symptoms.",
"   </p>",
"   <p>",
"    Symptoms such as nasal congestion, rhinorrhea, sneezing, and ocular itching may indicate allergic disease, and nasal congestion and rhinorrhea in the absence of itch and sneeze may suggest nasal polyposis. Chronic cough is another important clue to asthma in nonsmoking older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older patients with asthma seen in the outpatient setting usually have a normal physical exam of the chest, so a lack of expiratory wheezing, prolonged expiratory time, or hyperinflation of the chest wall does not rule-out asthma in a patient with a history of asthma-like symptoms. On the other hand, pale edematous nasal mucosa or the presence of nasal polyps may strengthen a diagnosis of asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SPIROMETRY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since older patients present a paucity of physical signs of asthma, spirometry should be performed for all patients with a history of dyspnea, chronic cough, asthma-like symptoms, or a history of smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/4,54,55\">",
"     4,54,55",
"    </a>",
"    ]. The majority of older individuals are able to perform spirometry, controverting concerns that frailty or decreased cognitive function would impair performance [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/56\">",
"     56",
"    </a>",
"    ]. One study of 5200 older patients found that good quality spirometry could be obtained over 90 percent of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spirometry to detect airway obstruction is easy and reliable when performed with office spirometers that comply with the National Lung Health Education Program (NLHEP) recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/58\">",
"     58",
"    </a>",
"    ]. These spirometers allow patients to stop each exhalation maneuver after only six seconds (FEV6), incorporate extensive maneuver quality checks, and interpret the results using the best reference equations for older people (NHANES III) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=see_link&amp;anchor=H2#H2\">",
"     \"Office spirometry\", section on 'Equipment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Airway obstruction is detected when both the FEV1 and the",
"    <span class=\"nowrap\">",
"     FEV1/FVC",
"    </span>",
"    from the best acceptable quality maneuver fall below the lower limit of the normal range (LLN). The LLN of",
"    <span class=\"nowrap\">",
"     FEV1/FVC",
"    </span>",
"    should not be determined using a fixed value of 70 percent for older patients (as currently recommended by the GOLD documents), since this will result in a high false positive rate [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/60\">",
"     60",
"    </a>",
"    ]. We suggest basing an interpretation of airflow obstruction on an",
"    <span class=\"nowrap\">",
"     FEV1/FVC",
"    </span>",
"    ratio of &lt;89 percent predicted (or below the LLN), using the Hankinson data set [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/59\">",
"     59",
"    </a>",
"    ]. The absence of airway obstruction does not rule out asthma, especially if the patient is not symptomatic at the time of testing, since airflow obstruction in asthma is, by definition, intermittent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=see_link&amp;anchor=H11#H11\">",
"     \"Office spirometry\", section on 'Ratio of FEV1/FVC'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     VARIABILITY IN AIRFLOW OBSTRUCTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bronchodilator response",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with an asthma diagnosis, older age does not alter the acute response to inhaled bronchodilator (BD) drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. The average time to peak effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    is 5 to 10 minutes in both young and older patients with asthma. The use of a combination of albuterol and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    bromide (Combivent, TM) for diagnostic testing will often produce more effective bronchodilation in older adults, but the peak effect takes 30 minutes to occur and the results are less specific for asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/63\">",
"     63",
"    </a>",
"    ]. In either case, the probability of asthma is substantially increased if the post-bronchodilator FEV1 increases more than 200 mL and the increase is more than 12 percent of the predicted value. If the post-bronchodilator FEV1",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ratio improve from obstruction into the normal range, then the test is diagnostic of asthma and COPD is essentially ruled out. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of pulmonary function testing in adults\", section on 'Post-bronchodilator'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The change in FEF25-75 percent should not be used to determine a bronchodilator response, since the FVC (and inspiratory capacity) often increases due to a reduction in air trapping in the lungs, making changes in FEF25-75 percent misleading [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Methacholine inhalation challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    challenge test (MCT) can be helpful in the differential diagnosis of dyspnea and cough in older patients with normal spirometry, who are not taking asthma medications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/50,62,65\">",
"     50,62,65",
"    </a>",
"    ]. With normal baseline spirometry, side effects from MCTs are rare, even in older persons. A low provocative challenge dose (PC-20) from the MCT (&lt;4",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    increases the probability of asthma in patients with asthma-like symptoms. The prevalence of bronchial hyperresponsiveness (BHR) is higher in older compared with middle-aged adults, even after correcting for the baseline degree of airways obstruction, smoking status, and atopy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/50\">",
"     50",
"    </a>",
"    ]. Therefore, a PC-20 threshold of &lt;4",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    to define bronchial hyperresponsiveness (BHR) in older patients may be more appropriate than the traditional &lt;8",
"    <span class=\"nowrap\">",
"     mg/mL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=see_link&amp;anchor=H11#H11\">",
"     \"Bronchoprovocation testing\", section on 'Methacholine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Home peak flow monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, lung function lability, as assessed by home peak flow monitoring, is modestly associated with asthma and BHR. However, the compliance and quality of home measurements of lung function in older persons is often suboptimal. Morning dips of 30 percent or more in PEF or FEV1 are abnormal in older people, and may help to diagnose asthma in a few patients, but high PEF lability predicts asthma poorly [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. Therefore, unless the patient is highly motivated, twice daily measurement of PEF at home for a couple of weeks is a poor substitute for a MCT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=see_link\">",
"     \"Peak expiratory flow rate monitoring in asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF ATOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with symptoms of exertional dyspnea, cough, or wheeze, the presence of atopy makes asthma more likely than COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/69\">",
"     69",
"    </a>",
"    ]. Although the atopy rate of the general population declines from middle-age (30 percent) to older-age (8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/13\">",
"     13",
"    </a>",
"    ], about three-fourths of older patients with asthma have a positive allergen skin test to aeroallergens, and about one-fourth of those with a cat or dog have become sensitized to their pet [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/5\">",
"     5",
"    </a>",
"    ]. Half of older patients with asthma living in the inner city in one study were sensitized to cockroach antigen, and this sensitivity was associated with more severe airways obstruction and hyperinflation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/17\">",
"     17",
"    </a>",
"    ]. We suggest assessing older adults with moderately severe to severe asthma for sensitivity to indoor allergens by one of the methods described below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Allergen skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major value of allergen skin testing is to guide specific interventions to reduce the patient's exposure to the allergens to which they have become sensitized [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. Allergen skin testing in the older patient should avoid atrophic or sun-damaged skin and should be adjusted for the size of the histamine wheal, in order to reduce the false negative rate [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/72\">",
"     72",
"    </a>",
"    ]. The cross sectional diameter of the test should be at least 3 mm larger than the histamine control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a small study, sera of older adults with asthma were more likely than patients without asthma to have a higher total IgE level and an elevated RAST (radioallergosorbent test) titer to the dust mite, Dermatophagoides pteronyssinus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/73\">",
"     73",
"    </a>",
"    ]. In general, skin prick testing is more sensitive than serologic tests for specific IgE, although this has not been specifically confirmed in older adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=see_link\">",
"     \"Overview of in vitro allergy tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Newer tests for airways inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the near future, the more widespread availability of non-invasive outpatient tests of airway inflammation, such as exhaled nitric oxide, breath condensate cytokines, and analysis of induced sputum may allow clinicians to differentiate between eosinophilic, neutrophilic, and lymphocytic bronchitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/74\">",
"     74",
"    </a>",
"    ]. These tests may enable more effective targeting of therapy for diseases of airway inflammation in older patients by differentiating between asthma and COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confirmation of the diagnosis of asthma is based on the presence of respiratory symptoms suggestive of asthma and the demonstration of variable expiratory airflow obstruction. Variability in airflow obstruction may be apparent from measurements made at different points in time, in response to an asthma trigger, or after asthma therapy. As an example, a patient's FEV1 might vary from one visit to the next, before and after inhalation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"     methacholine",
"    </a>",
"    , or before and after inhaled bronchodilator. The NAEPP guidelines recommend spirometry pre and post bronchodilator. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link\">",
"     \"Diagnosis of asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=see_link\">",
"     \"Use of pulmonary function testing in the diagnosis of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of intermittent respiratory symptoms in older adults in many cases is more difficult than in younger adults due to the higher prevalence of non-asthma conditions among older patients with dyspnea. A list of causes of chronic respiratory symptoms in older adults is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef80068 \" href=\"UTD.htm?2/33/2588\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The three most common causes of chronic or intermittent dyspnea in older adults are COPD, heart failure (HF), and asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/75\">",
"     75",
"    </a>",
"    ]. The differential diagnosis can be challenging since the three diseases share a common risk factor (cigarette smoking) and have many symptoms in common such as intermittent dyspnea, cough, wheezing, chest tightness, nocturnal symptoms, and worsening with exercise. Sometimes, deconditioning can be differentiated from dyspnea due to a disease process: deconditioning is often described as fatigue and dyspnea as increased effort to breathe, air hunger, or chest tightness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=see_link\">",
"     \"Approach to the patient with dyspnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     COPD versus asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pretest probability of COPD in a patient with a substantial (particularly past) smoking history and airflow limitation is much higher than for asthma. However, not all airway obstruction in a current or former smoker is due to COPD and the clinician should be mindful of alternative diagnoses such as asthma, particularly if spirometry is performed when the patient is acutely ill. Airflow obstruction that is significantly or completely reversible with inhaled bronchodilator favors a diagnosis of asthma. In current or former smokers with airway obstruction but without a large bronchodilator response, a low diffusing capacity (DLCO) will strongly suggest COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. A chest CT scan may also be helpful to identify emphysema if there is doubt as to the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Heart failure versus asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differentiation of HF from asthma in the ambulatory setting may be challenging, particularly when the disease is mild. Objective evidence of elevated jugular venous pressure, S3, peripheral edema, vascular congestion on chest radiograph, and systolic dysfunction on echocardiography all increase the probability of HF. Intermittent symptoms of dyspnea in the absence of these signs should not be attributed to diastolic dysfunction without consideration of obstructive airways disease, among other diagnoses. Evidence of airflow obstruction on spirometry defines obstructive airways disease. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Spirometry'",
"    </a>",
"    above.) Cardiovascular disease in ambulatory older persons usually causes only a mild reduction in the FEV1 and FVC of approximately 0.1 to 0.3 liters [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/78\">",
"     78",
"    </a>",
"    ]. Substantial airway obstruction in a patient presenting to the emergency department or in the hospital is much more likely due to asthma or COPD than HF [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with acute dyspnea, chest x-ray and measurement of B-type natriuretic peptide (BNP) may help identify the cause [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=see_link\">",
"     \"Approach to the patient with dyspnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful management of asthma in older adults is based on the same four essential components (monitoring, education, control of environmental factors, and pharmacologic therapy) that are used for management of asthma at all ages. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The NAEPP recommends a stepwise approach to therapy, starting with a determination of asthma severity to guide initial therapy and followed by adjustments based on asthma control (",
"    <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53233 \" href=\"UTD.htm?38/33/39453\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The comments below outline considerations that specifically pertain to older adults. As with younger patients, a written asthma action plan is important to achieve optimal care [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/10,82\">",
"     10,82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Inhaler technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some older patients have difficulty learning correct inhaler technique; an abnormal Mini-Mental State Examination predicts difficulty learning and retaining inhaler technique [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link\">",
"     \"Evaluation of cognitive impairment and dementia\"",
"    </a>",
"    .) Use of an HFA pressurized metered dose (MDI) device with a valved holding chamber, a breath actuated dry powder inhaler, or a nebulizer may improve medication delivery when technique is suboptimal [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=see_link\">",
"     \"Delivery of inhaled medication in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled glucocorticoids (inhaled GC) are the recommended controller therapy for patients with moderately severe to severe persistent asthma and have been shown to reduce mortality and hospitalization in elderly patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/88\">",
"     88",
"    </a>",
"    ]. Initiation of inhaled GC should follow the NAEPP guidelines (",
"    <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78011 \" href=\"UTD.htm?15/35/15934\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/71\">",
"     71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When asthma is not well-controlled on low dose inhaled GC, possible causes of poor adherence should first be considered, such as the cost of the inhalers, difficulty using the inhaler, depression, or worries about steroid side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]. Occult smoking, which decreases the effectiveness of ICS therapy, may also be playing a role.",
"   </p>",
"   <p>",
"    The likely efficacy and side effects of \"steps up\" in therapy, such as increasing the dose of inhaled GC or adding another controller agent, such as a long acting beta-agonist (LABA) or an antileukotriene (",
"    <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"     figure 1",
"    </a>",
"    ), should be considered. In older adults with atrial fibrillation or coronary heart disease, increasing the dose of inhaled GC or adding an antileukotriene might be preferable to adding a LABA. On the other hand, in a patient with osteoporosis or glaucoma, it might be preferable to add a LABA or an antileukotriene agent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26745?source=see_link\">",
"     \"Treatment of moderate persistent asthma in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    for asthma should be limited to short-term \"bursts\", to treat an exacerbation of asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    .) Another indication might be a brief course of oral glucocorticoid in a patient with airflow obstruction that is not reversible with bronchodilator to clarify a diagnosis of asthma (at least partially reversible) or COPD (not reversible).",
"   </p>",
"   <p>",
"    Chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy should be used only as a last resort, after the clinician has helped the patient identify and minimize exacerbating factors (environmental, drug, GERD, and rhinosinusitis), prescribed a moderate to high daily dose of inhaled GC for at least three months, tried a long-acting beta-agonist",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a leukotriene modifier, and examined the patient closely for comorbidities that will be worsened by glucocorticoid therapy.",
"   </p>",
"   <p>",
"    Chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy has multiple potential side effects in older patients, especially older women, including hip and vertebral fractures, cataracts, poor glycemic control, and varicella zoster [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/92\">",
"     92",
"    </a>",
"    ]. High daily doses of inhaled GC may also decrease bone mineral density and increase the risk of fracture, although data are conflicting (",
"    <a class=\"graphic graphic_table graphicRef81103 \" href=\"UTD.htm?28/63/29693\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/92-94\">",
"     92-94",
"    </a>",
"    ]. Adult patients receiving chronic therapy with inhaled GC and who have a moderate risk of osteoporosis should undergo bone density measurement to assess the need for preventive therapy, as is recommended for patients receiving inhaled GC for COPD (",
"    <a class=\"graphic graphic_table graphicRef70743 \" href=\"UTD.htm?32/11/32955\">",
"     table 7",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=see_link\">",
"     \"Major side effects of inhaled glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Bronchodilator therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-acting inhaled beta-2-selective adrenergic agonist (SABA) therapy is recommended as needed for relief of acute asthma symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/71,95\">",
"     71,95",
"    </a>",
"    ]. According to the NAEPP and GINA guidelines, long-acting beta-agonist (LABA) therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    is indicated in patients with persistent asthma whose asthma is not well-controlled on inhaled GC alone (",
"    <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68143 \" href=\"UTD.htm?37/48/38668\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/71,95\">",
"     71,95",
"    </a>",
"    ]. However, the safety of salmeterol in older adults with asthma has not been directly assessed in large groups of patients and the overall safety of LABAs for asthma has been questioned in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/96-100\">",
"     96-100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one of the larger studies of LABA safety, the SMART trial, the exact number of older patients was not provided, but two of the thirteen deaths were in patients over age 65, and one of these was a patient with oxygen dependent COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/100\">",
"     100",
"    </a>",
"    ]. On the other hand, it may be reassuring to note that patients with COPD experience no greater morbidity when using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    compared with fluticasone alone [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/101\">",
"     101",
"    </a>",
"    ]. Generally, in older adults with asthma, the dose given twice daily should be limited to 50 mcg for salmeterol and 12 mcg for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    , in order to limit the risk of cardiovascular toxicity.",
"   </p>",
"   <p>",
"    Anticholinergic therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/34/27173?source=see_link\">",
"     tiotropium",
"    </a>",
"    has not been found to be effective as a controller agent for asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. It may be beneficial in patients who have both asthma and COPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Theophylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     Theophylline",
"    </a>",
"    is not suggested for the routine treatment of asthma in older adults. Chronic overmedication with theophylline remains common and causes major toxic events [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Anti-leukotriene agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steroid-sparing therapy is a reasonable option before increasing inhaled corticosteroid therapy to high daily doses in older patients. In one large four week, open-label trial of leukotriene antagonist therapy, asthma symptoms improved in 54 percent of older patients with mild asthma, 63 percent with moderate asthma, and 70 percent with severe asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/105\">",
"     105",
"    </a>",
"    ]. Improvements in pulmonary function testing and reduction in beta-agonist use were not as great among elderly patients as adolescent and adult patients with asthma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30746?source=see_link\">",
"     \"Agents affecting the 5-lipoxygenase pathway in the treatment of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both influenza and pneumococcal vaccines reduce respiratory infections in asthmatics [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. In a retrospective review, pneumococcal vaccination was associated with a decrease in asthma admissions in elderly patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Trigger mitigation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although trials of allergen mitigation (efforts to reduce indoor allergen levels) that include older adults are lacking, mitigation is helpful in children. Environmental modifications based on allergen skin test results are suggested for older adults with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/109\">",
"     109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"     \"Trigger control to enhance asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Smoking cessation is clearly important patients with asthma and can reduce fatal and nonfatal cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/43/5818/abstract/110\">",
"     110",
"    </a>",
"    ]. Similarly, avoidance of other asthma triggers may reduce the frequency of asthma exacerbations (",
"    <a class=\"graphic graphic_table graphicRef52067 \" href=\"UTD.htm?19/49/20254\">",
"     table 9",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asthma is common in adults over age 65. Some patients will have had asthma since childhood and others may have developed asthma as adults. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Older patients with asthma are just as likely to report cough, wheeze and chest tightness as younger patients. However, older patients are less likely to report dyspnea at a given degree of airflow limitation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although older adults with asthma are less likely to be atopic than younger adults, atopy is still common and three-fourths will have a positive skin test to at least one indoor allergen. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Atopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Identifying and avoiding asthma triggers (eg, smoke or smoking) often helps control asthma symptoms and is free of side effects (",
"      <a class=\"graphic graphic_table graphicRef80507 \" href=\"UTD.htm?34/33/35357\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef52067 \" href=\"UTD.htm?19/49/20254\">",
"       table 9",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"       \"Trigger control to enhance asthma management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Spirometry is accurate in most older adults and an important part of the diagnosis and management of asthma. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Spirometry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tests of bronchodilator and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/32/10756?source=see_link\">",
"       methacholine",
"      </a>",
"      responsiveness are accurate in most older adults and help in the diagnosis of asthma. Tests of diffusing capacity and measurement of bronchodilator response help to differentiate asthma from COPD. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Variability in airflow obstruction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'COPD versus asthma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that acute asthma symptoms be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Bronchodilator therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with only intermittent asthma, we suggest not using any controller therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients with mild persistent asthma, we suggest treatment with controller therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In patients with asthma more severe than this, we recommend controller therapy (",
"      <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"       table 3",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend inhaled GC, started at a low to medium dose, as initial controller therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). In patients who do not respond to low dose inhaled GC, we usually suggest increasing the dose (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, in some patients at high risk for steroid side effects (eg, osteoporosis or glaucoma), it may be preferable to add a LABA or antileukotriene agent, so as to maintain a lower dose of inhaled GC (",
"      <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of cardiovascular disease, we suggest adding a LABA in patients who are inadequately controlled on medium to high dose inhaled GC or do not tolerate higher doses of inhaled GC (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Leukotriene receptor antagonists are an alternative. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Bronchodilator therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Anti-leukotriene agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest not using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      to treat asthma in older adults (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Theophylline'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/1\">",
"      Mannino DM, Homa DM, Akinbami LJ, et al. Surveillance for asthma--United States, 1980-1999. MMWR Surveill Summ 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/2\">",
"      Enright PL, McClelland RL, Newman AB, et al. Underdiagnosis and undertreatment of asthma in the elderly. Cardiovascular Health Study Research Group. Chest 1999; 116:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/3\">",
"      Parameswaran K, Hildreth AJ, Chadha D, et al. Asthma in the elderly: underperceived, underdiagnosed and undertreated; a community survey. Respir Med 1998; 92:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/4\">",
"      Dow L, Fowler L, Phelps L, et al. Prevalence of untreated asthma in a population sample of 6000 older adults in Bristol, UK. Thorax 2001; 56:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/5\">",
"      Huss K, Naumann PL, Mason PJ, et al. Asthma severity, atopic status, allergen exposure and quality of life in elderly persons. Ann Allergy Asthma Immunol 2001; 86:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/6\">",
"      Bellia V, Battaglia S, Catalano F, et al. Aging and disability affect misdiagnosis of COPD in elderly asthmatics: the SARA study. Chest 2003; 123:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/7\">",
"      Stupka E, deShazo R. Asthma in seniors: Part 1. Evidence for underdiagnosis, undertreatment, and increasing morbidity and mortality. Am J Med 2009; 122:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/8\">",
"      Enright PL, Kronmal RA, Higgins MW, et al. Prevalence and correlates of respiratory symptoms and disease in the elderly. Cardiovascular Health Study. Chest 1994; 106:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/9\">",
"      Diette GB, Krishnan JA, Dominici F, et al. Asthma in older patients: factors associated with hospitalization. Arch Intern Med 2002; 162:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/10\">",
"      Slavin RG, Haselkorn T, Lee JH, et al. Asthma in older adults: observations from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study. Ann Allergy Asthma Immunol 2006; 96:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/11\">",
"      Moorman JE, Mannino DM. Increasing U.S. asthma mortality rates: who is really dying? J Asthma 2001; 38:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/12\">",
"      Bellia V, Pedone C, Catalano F, et al. Asthma in the elderly: mortality rate and associated risk factors for mortality. Chest 2007; 132:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/13\">",
"      Gergen PJ, Turkeltaub PC, Kovar MG. The prevalence of allergic skin test reactivity to eight common aeroallergens in the U.S. population: results from the second National Health and Nutrition Examination Survey. J Allergy Clin Immunol 1987; 80:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/14\">",
"      Barbee RA, Kaltenborn W, Lebowitz MD, Burrows B. Longitudinal changes in allergen skin test reactivity in a community population sample. J Allergy Clin Immunol 1987; 79:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/15\">",
"      Kerkhof M, Postma DS, Schouten JP, de Monchy JG. Allergic sensitization to indoor and outdoor allergens and relevance to bronchial hyperresponsiveness in younger and older subjects. Allergy 2003; 58:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/16\">",
"      Litonjua AA, Sparrow D, Weiss ST, et al. Sensitization to cat allergen is associated with asthma in older men and predicts new-onset airway hyperresponsiveness. The Normative Aging Study. Am J Respir Crit Care Med 1997; 156:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/17\">",
"      Rogers L, Cassino C, Berger KI, et al. Asthma in the elderly: cockroach sensitization and severity of airway obstruction in elderly nonsmokers. Chest 2002; 122:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/18\">",
"      Weiss ST, O'Connor GT, DeMolles D, et al. Indoor allergens and longitudinal FEV1 decline in older adults: the Normative Aging Study. J Allergy Clin Immunol 1998; 101:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/19\">",
"      Thorn J, Brisman J, Tor&eacute;n K. Adult-onset asthma is associated with self-reported mold or environmental tobacco smoke exposures in the home. Allergy 2001; 56:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/20\">",
"      Jaakkola MS, Nordman H, Piipari R, et al. Indoor dampness and molds and development of adult-onset asthma: a population-based incident case-control study. Environ Health Perspect 2002; 110:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/21\">",
"      Mitsunobu F, Ashida K, Hosaki Y, et al. Influence of long-term cigarette smoking on immunoglobulin E-mediated allergy, pulmonary function, and high-resolution computed tomography lung densitometry in elderly patients with asthma. Clin Exp Allergy 2004; 34:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/22\">",
"      Mishra V. Effect of indoor air pollution from biomass combustion on prevalence of asthma in the elderly. Environ Health Perspect 2003; 111:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/23\">",
"      McDonnell WF, Abbey DE, Nishino N, Lebowitz MD. Long-term ambient ozone concentration and the incidence of asthma in nonsmoking adults: the AHSMOG Study. Environ Res 1999; 80:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/24\">",
"      Arif AA, Delclos GL, Whitehead LW, et al. Occupational exposures associated with work-related asthma and work-related wheezing among U.S. workers. Am J Ind Med 2003; 44:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/25\">",
"      Karjalainen A, Kurppa K, Martikainen R, et al. Work is related to a substantial portion of adult-onset asthma incidence in the Finnish population. Am J Respir Crit Care Med 2001; 164:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/26\">",
"      Forastiere F, Balmes J, Scarinci M, Tager IB. Occupation, asthma, and chronic respiratory symptoms in a community sample of older women. Am J Respir Crit Care Med 1998; 157:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/27\">",
"      Schwartz J. Air pollution and hospital admissions for respiratory disease. Epidemiology 1996; 7:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/28\">",
"      Atkinson RW, Anderson HR, Sunyer J, et al. Acute effects of particulate air pollution on respiratory admissions: results from APHEA 2 project. Air Pollution and Health: a European Approach. Am J Respir Crit Care Med 2001; 164:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/29\">",
"      Gal&aacute;n I, Tob&iacute;as A, Banegas JR, Ar&aacute;nguez E. Short-term effects of air pollution on daily asthma emergency room admissions. Eur Respir J 2003; 22:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/30\">",
"      Karpati AM, Perrin MC, Matte T, et al. Pesticide spraying for West Nile virus control and emergency department asthma visits in New York City, 2000. Environ Health Perspect 2004; 112:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/31\">",
"      Desqueyroux H, Pujet JC, Prosper M, et al. Short-term effects of low-level air pollution on respiratory health of adults suffering from moderate to severe asthma. Environ Res 2002; 89:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/32\">",
"      Anderson HR, Ponce de Leon A, Bland JM, et al. Air pollution, pollens, and daily admissions for asthma in London 1987-92. Thorax 1998; 53:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/33\">",
"      Horak F Jr, Studnicka M, Gartner C, et al. Particulate matter and lung function growth in children: a 3-yr follow-up study in Austrian schoolchildren. Eur Respir J 2002; 19:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/34\">",
"      Andersen ZJ, B&oslash;nnelykke K, Hvidberg M, et al. Long-term exposure to air pollution and asthma hospitalisations in older adults: a cohort study. Thorax 2012; 67:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/35\">",
"      Gauderman WJ, Avol E, Gilliland F, et al. The effect of air pollution on lung development from 10 to 18 years of age. N Engl J Med 2004; 351:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/36\">",
"      Ishioka S, Terada M, Haruta Y, et al. Multiple logistic regression analysis of risk factors for the development of steroid-dependent asthma in the elderly: a comparison with younger asthmatics. Respiration 2001; 68:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/37\">",
"      Braman SS. Asthma in the elderly. Clin Geriatr Med 2003; 19:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/38\">",
"      Garshick E, Laden F, Hart JE, Caron A. Residence near a major road and respiratory symptoms in U.S. Veterans. Epidemiology 2003; 14:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/39\">",
"      Mapp CE, Boschetto P, Maestrelli P, Fabbri LM. Occupational asthma. Am J Respir Crit Care Med 2005; 172:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/40\">",
"      Balmes JR. Occupational contribution to the burden of chronic obstructive pulmonary disease. J Occup Environ Med 2005; 47:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/41\">",
"      Trupin L, Earnest G, San Pedro M, et al. The occupational burden of chronic obstructive pulmonary disease. Eur Respir J 2003; 22:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/42\">",
"      Barr RG, Somers SC, Speizer FE, et al. Patient factors and medication guideline adherence among older women with asthma. Arch Intern Med 2002; 162:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/43\">",
"      Luder E, Ehrlich RI, Lou WY, et al. Body mass index and the risk of asthma in adults. Respir Med 2004; 98:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/44\">",
"      Ford ES. The epidemiology of obesity and asthma. J Allergy Clin Immunol 2005; 115:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/45\">",
"      Kos-Kudla B, Ostrowska Z, Marek B, et al. Circadian serum levels of dehydroepiandrosterone sulphate in postmenopausal asthmatic women before and after long-term hormone replacement. Endocr Regul 2001; 35:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/46\">",
"      Carlson CL, Cushman M, Enright PL, et al. Hormone replacement therapy is associated with higher FEV1 in elderly women. Am J Respir Crit Care Med 2001; 163:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/47\">",
"      Barr RG, Wentowski CC, Grodstein F, et al. Prospective study of postmenopausal hormone use and newly diagnosed asthma and chronic obstructive pulmonary disease. Arch Intern Med 2004; 164:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/48\">",
"      Diggory P, Heyworth P, Chau G, et al. Unsuspected bronchospasm in association with topical timolol--a common problem in elderly people: can we easily identify those affected and do cardioselective agents lead to improvement? Age Ageing 1994; 23:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/49\">",
"      Brooks TW, Creekmore FM, Young DC, et al. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers. Pharmacotherapy 2007; 27:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/50\">",
"      Cuttitta G, Cibella F, Bellia V, et al. Changes in FVC during methacholine-induced bronchoconstriction in elderly patients with asthma: bronchial hyperresponsiveness and aging. Chest 2001; 119:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/51\">",
"      Quadrelli SA, Roncoroni A. Features of asthma in the elderly. J Asthma 2001; 38:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/52\">",
"      Weiner P, Magadle R, Waizman J, et al. Characteristics of asthma in the elderly. Eur Respir J 1998; 12:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/53\">",
"      Smyrnios NA, Irwin RS, Curley FJ, French CL. From a prospective study of chronic cough: diagnostic and therapeutic aspects in older adults. Arch Intern Med 1998; 158:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/54\">",
"      Camhi, SL, Enright, PL. How to assess pulmonary function in older adults. J Respir Dis 2000; 21:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/55\">",
"      Zaas D, Wise R, Wiener C, Longcope Spirometry Invetigation Team. Airway obstruction is common but unsuspected in patients admitted to a general medicine service. Chest 2004; 125:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/56\">",
"      Sherman CB, Kern D, Richardson ER, et al. Cognitive function and spirometry performance in the elderly. Am Rev Respir Dis 1993; 148:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/57\">",
"      Enright PL, Kronmal RA, Higgins M, et al. Spirometry reference values for women and men 65 to 85 years of age. Cardiovascular health study. Am Rev Respir Dis 1993; 147:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/58\">",
"      Ferguson GT, Enright PL, Buist AS, Higgins MW. Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program. Chest 2000; 117:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/59\">",
"      Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/60\">",
"      Hardie JA, Buist AS, Vollmer WM, et al. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002; 20:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/61\">",
"      Kradjan WA, Driesner NK, Abuan TH, et al. Effect of age on bronchodilator response. Chest 1992; 101:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/62\">",
"      Parker AL. Aging does not affect beta-agonist responsiveness after methacholine-induced bronchoconstriction. J Am Geriatr Soc 2004; 52:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/63\">",
"      Dorinsky PM, Reisner C, Ferguson GT, et al. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999; 115:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/64\">",
"      Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis 1991; 144:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/65\">",
"      Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000; 161:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/66\">",
"      Enright PL. The diagnosis and management of asthma is much tougher in older patients. Curr Opin Allergy Clin Immunol 2002; 2:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/67\">",
"      K&uuml;nzli N, Stutz EZ, Perruchoud AP, et al. Peak flow variability in the SAPALDIA study and its validity in screening for asthma-related conditions. The SPALDIA Team. Am J Respir Crit Care Med 1999; 160:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/68\">",
"      Goldstein MF, Veza BA, Dunsky EH, et al. Comparisons of peak diurnal expiratory flow variation, postbronchodilator FEV(1) responses, and methacholine inhalation challenges in the evaluation of suspected asthma. Chest 2001; 119:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/69\">",
"      Sin BA, Akkoca O, Saryal S, et al. Differences between asthma and COPD in the elderly. J Investig Allergol Clin Immunol 2006; 16:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/70\">",
"      Crain EF, Walter M, O'Connor GT, et al. Home and allergic characteristics of children with asthma in seven U.S. urban communities and design of an environmental intervention: the Inner-City Asthma Study. Environ Health Perspect 2002; 110:939.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on January 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/72\">",
"      King MJ, Lockey RF. Allergen prick-puncture skin testing in the elderly. Drugs Aging 2003; 20:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/73\">",
"      King MJ, Bukantz SC, Phillips S, et al. Serum total IgE and specific IgE to Dermatophagoides pteronyssinus, but not eosinophil cationic protein, are more likely to be elevated in elderly asthmatic patients. Allergy Asthma Proc 2004; 25:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/74\">",
"      Sutherland ER, Martin RJ. Airway inflammation in chronic obstructive pulmonary disease: comparisons with asthma. J Allergy Clin Immunol 2003; 112:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/75\">",
"      Yernault JC. Dyspnoea in the elderly: a clinical approach to diagnosis. Drugs Aging 2001; 18:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/76\">",
"      American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique--1995 update. Am J Respir Crit Care Med 1995; 152:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/77\">",
"      Goedhart DM, Zanen P, Lammers JW. Relevant and redundant lung function parameters in discriminating asthma from COPD. COPD 2006; 3:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/78\">",
"      Enright PL, Kronmal RA, Smith VE, et al. Reduced vital capacity in elderly persons with hypertension, coronary heart disease, or left ventricular hypertrophy. The Cardiovascular Health Study. Chest 1995; 107:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/79\">",
"      Ailani RK, Ravakhah K, DiGiovine B, et al. Dyspnea differentiation index: A new method for the rapid separation of cardiac vs pulmonary dyspnea. Chest 1999; 116:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/80\">",
"      McCullough PA, Hollander JE, Nowak RM, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med 2003; 10:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/81\">",
"      Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002; 39:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/82\">",
"      Buist AS, Vollmer WM, Wilson SR, et al. A randomized clinical trial of peak flow versus symptom monitoring in older adults with asthma. Am J Respir Crit Care Med 2006; 174:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/83\">",
"      Allen SC, Jain M, Ragab S, Malik N. Acquisition and short-term retention of inhaler techniques require intact executive function in elderly subjects. Age Ageing 2003; 32:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/84\">",
"      Allen SC, Warwick-Sanders M, Baxter M. A comparison of four tests of cognition as predictors of inability to learn to use a metered dose inhaler in old age. Int J Clin Pract 2009; 63:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/85\">",
"      Rabell-Santacana V, Pastor-Ramon E, Pujol-Rib&oacute; J, et al. [Inhaled drug use in elderly patients and limitations in association with geriatric assessment scores]. Arch Bronconeumol 2008; 44:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/86\">",
"      Marcus P, Oppenheimer EA, Patel PA, et al. Use of nebulized inhaled corticosteroids among older adult patients: an assessment of outcomes. Ann Allergy Asthma Immunol 2006; 96:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/87\">",
"      Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005; 127:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/88\">",
"      Schmier JK, Halpern MT, Jones ML. Effects of inhaled corticosteroids on mortality and hospitalisation in elderly asthma and chronic obstructive pulmonary disease patients: appraising the evidence. Drugs Aging 2005; 22:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/89\">",
"      Rimington LD, Davies DH, Lowe D, Pearson MG. Relationship between anxiety, depression, and morbidity in adult asthma patients. Thorax 2001; 56:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/90\">",
"      Balkrishnan R, Christensen DB, Bowton DL. Self-reported health status, prophylactic medication use, and healthcare costs in older adults with asthma. J Am Geriatr Soc 2002; 50:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/91\">",
"      Hartert TV, Togias A, Mellen BG, et al. Underutilization of controller and rescue medications among older adults with asthma requiring hospital care. J Am Geriatr Soc 2000; 48:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/92\">",
"      Walsh LJ, Wong CA, Oborne J, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001; 56:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/93\">",
"      Hubbard R, Tattersfield A, Smith C, et al. Use of inhaled corticosteroids and the risk of fracture. Chest 2006; 130:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/94\">",
"      Suissa S, Baltzan M, Kremer R, Ernst P. Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 2004; 169:83.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.ginasthma.org/Guidelines/guidelines-resources.html (Accessed on January 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/96\">",
"      Meier CR, Jick H. Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK. Thorax 1997; 52:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/97\">",
"      Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004; 125:2309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/98\">",
"      Cazzola M, Imperatore F, Salzillo A, et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998; 114:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/99\">",
"      Ferguson GT, Funck-Brentano C, Fischer T, et al. Cardiovascular safety of salmeterol in COPD. Chest 2003; 123:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/100\">",
"      Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/101\">",
"      Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/102\">",
"      Westby M, Benson M, Gibson P. Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst Rev 2004; :CD003269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/103\">",
"      Restrepo RD. Use of inhaled anticholinergic agents in obstructive airway disease. Respir Care 2007; 52:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/104\">",
"      Shannon M. Life-threatening events after theophylline overdose: a 10-year prospective analysis. Arch Intern Med 1999; 159:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/105\">",
"      Korenblat PE, Kemp JP, Scherger JE, et al. Effect of age on response to zafirlukast in patients with asthma in the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT). Ann Allergy Asthma Immunol 2000; 84:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/106\">",
"      Voordouw BC, van der Linden PD, Simonian S, et al. Influenza vaccination in community-dwelling elderly: impact on mortality and influenza-associated morbidity. Arch Intern Med 2003; 163:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/107\">",
"      Tata LJ, West J, Harrison T, et al. Does influenza vaccination increase consultations, corticosteroid prescriptions, or exacerbations in subjects with asthma or chronic obstructive pulmonary disease? Thorax 2003; 58:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/108\">",
"      Ansaldi F, Turello V, Lai P, et al. Effectiveness of a 23-valent polysaccharide vaccine in preventing pneumonia and non-invasive pneumococcal infection in elderly people: a large-scale retrospective cohort study. J Int Med Res 2005; 33:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/109\">",
"      Morgan WJ, Crain EF, Gruchalla RS, et al. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med 2004; 351:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/43/5818/abstract/110\">",
"      Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166:333.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 521 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-222.169.60.2-D2BD478EF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_43_5818=[""].join("\n");
var outline_f5_43_5818=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Atopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Irritant exposures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Comorbid conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SPIROMETRY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      VARIABILITY IN AIRFLOW OBSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bronchodilator response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Methacholine inhalation challenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Home peak flow monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ASSESSMENT OF ATOPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Allergen skin testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Serologic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Newer tests for airways inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      COPD versus asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Heart failure versus asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Inhaler technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Bronchodilator therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Theophylline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Anti-leukotriene agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Trigger mitigation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/521\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/521|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/33/44563\" title=\"figure 1\">",
"      Stepwise asthma Rx 12 and up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/521|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/33/35357\" title=\"table 1\">",
"      Asthma trigger questions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/33/2588\" title=\"table 2\">",
"      Differential diagnosis of asthma in older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/48/33549\" title=\"table 3\">",
"      Initiating Rx 12 and up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/33/39453\" title=\"table 4\">",
"      Adjusting Rx 12 and up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/35/15934\" title=\"table 5\">",
"      Inhaled GC doses for adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/63/29693\" title=\"table 6\">",
"      Studies of inhaled glucocorticoids and bone mineral density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/11/32955\" title=\"table 7\">",
"      Osteoporosis prevention in COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/48/38668\" title=\"table 8\">",
"      Usual doses inhaled GC-LABA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/49/20254\" title=\"table 9\">",
"      Asthma trigger guide",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30746?source=related_link\">",
"      Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=related_link\">",
"      Approach to the patient with dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/4/1098?source=related_link\">",
"      Bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/14/30954?source=related_link\">",
"      Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=related_link\">",
"      Delivery of inhaled medication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=related_link\">",
"      Office spirometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44391?source=related_link\">",
"      Overview of in vitro allergy tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=related_link\">",
"      Peak expiratory flow rate monitoring in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=related_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26745?source=related_link\">",
"      Treatment of moderate persistent asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=related_link\">",
"      Trigger control to enhance asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/61/22487?source=related_link\">",
"      Use of pulmonary function testing in the diagnosis of asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_43_5819="Causes platelet transfusion refractoriness";
var content_f5_43_5819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F67416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F67416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes for refractoriness to platelet transfusion",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sepsis and/or infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Splenomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alloimmunization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ABO mismatch",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Less common",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematopoietic cell transplantation - autologous or allogeneic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disseminated intravascular coagulation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_43_5819=[""].join("\n");
var outline_f5_43_5819=null;
var title_f5_43_5820="Recommended maintenance doses";
var content_f5_43_5820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F78503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F78503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended dosing with US standardized extracts",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Allergen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Extracts available",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosing by average major allergen content",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosing recommended in practice parameters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short ragweed",
"       </td>",
"       <td>",
"        1:10 w/v (100,000 AU/mL)",
"       </td>",
"       <td>",
"        2500 AU",
"       </td>",
"       <td>",
"        1000 to 4000 AU",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Dermatophagoides pteronyssinus",
"        </em>",
"       </td>",
"       <td>",
"        3000, 5000, 10,000 and 30,000 AU/mL",
"       </td>",
"       <td>",
"        1000 AU",
"       </td>",
"       <td>",
"        500 to 2000 AU",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Dermatophagoides farinae",
"        </em>",
"       </td>",
"       <td>",
"        3000, 5000, 10,000 and 30,000 AU/mL",
"       </td>",
"       <td>",
"        1500 AU",
"       </td>",
"       <td>",
"        500 to 2000 AU",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cat hair or pelt",
"       </td>",
"       <td>",
"        5000 and 10,000 BAU/mL",
"       </td>",
"       <td>",
"        3750 BAU",
"       </td>",
"       <td>",
"        1000 to 4000 BAU",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Timothy grass",
"       </td>",
"       <td>",
"        100,000 BAU/mL",
"       </td>",
"       <td>",
"        3000 BAU",
"       </td>",
"       <td>",
"        1000 to 4000 BAU",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bermuda grass",
"       </td>",
"       <td>",
"        10,000 BAU/mL",
"       </td>",
"       <td>",
"        1000 BAU",
"       </td>",
"       <td>",
"        300 to 1500 BAU",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AP dog",
"       </td>",
"       <td>",
"        1:100 w/v",
"       </td>",
"       <td>",
"        0.10 mL 1:100 w/v",
"       </td>",
"       <td>",
"        0.04 to 0.19 mL 1:100 w/v",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     w/v: weight/volume; AU: allergy unit; BAU: bioequivalent allergy unit.",
"    </div>",
"    <div class=\"reference\">",
"     Reference: Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127:S1-55.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_43_5820=[""].join("\n");
var outline_f5_43_5820=null;
var title_f5_43_5821="ACLS AF rate rhythm control I";
var content_f5_43_5821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for the control of rate and rhythm in atrial fibrillation/flutter-I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Cardiac function preserved",
"      </td>",
"      <td class=\"subtitle1\">",
"       Impaired cardiac function EF &lt;40 percent or HF",
"      </td>",
"      <td class=\"subtitle1\">",
"       Duration &lt;48 hours",
"      </td>",
"      <td class=\"subtitle1\">",
"       Duration &gt;48 hours or unknown",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Normal cardiac function",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Note: If AF &gt;48 hours duration, use agents to convert rhythm with extreme caution in patients not receiving adequate anticoagulation because of possible embolic complications.",
"       </p>",
"       <p>",
"        <strong>",
"         Use only 1 of the following agents:",
"        </strong>",
"       </p>",
"       <p>",
"        Calcium channel blockers (Class 1)",
"       </p>",
"       <p>",
"        Beta-blockers (Class 1)",
"       </p>",
"       <p>",
"        Additional drugs are Class lIb recommendations",
"       </p>",
"      </td>",
"      <td>",
"       (Does not apply)",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         Consider:",
"        </strong>",
"        DC cardioversion",
"       </p>",
"       <p>",
"        <strong>",
"         Use only 1 of the following agents:",
"        </strong>",
"       </p>",
"       <p>",
"        Amiodarone (Class Ila)",
"       </p>",
"       <p>",
"        Ibutilide (Class Ila)",
"       </p>",
"       <p>",
"        Flecainide (Class Ila)",
"       </p>",
"       <p>",
"        Propafenone (Class Ila)",
"       </p>",
"       <p>",
"        Procainamide (Class Ila)",
"       </p>",
"       <p>",
"        Other drugs are Class IIb recommendations",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         NO DC cardioversion!",
"        </strong>",
"       </p>",
"       <p>",
"        Note: Conversion of AF to NSR with drugs or shock may cause embolization of atrial thrombi unless patient has adequate anticoagulation.",
"       </p>",
"       <p>",
"        Use antiarrhythmic agents with extreme caution if AF &gt;48 hours duration.",
"       </p>",
"       <p>",
"        <strong>",
"         OR",
"        </strong>",
"       </p>",
"       <p>",
"        <strong>",
"         Delayed cardioversion anticoagulation x3 weeks at proper levels",
"        </strong>",
"       </p>",
"       <p>",
"        Cardioversion, then Anticoagulation x4 weeks more",
"       </p>",
"       <p>",
"        <strong>",
"         OR",
"        </strong>",
"       </p>",
"       <p>",
"        <strong>",
"         Early cardioversion",
"        </strong>",
"       </p>",
"       <p>",
"        Begin IV heparin at once",
"       </p>",
"       <p>",
"        TEE to exclude atrial clot",
"       </p>",
"       <p>",
"        <strong>",
"         THEN",
"        </strong>",
"       </p>",
"       <p>",
"        Cardioversion within 24 hours",
"       </p>",
"       <p>",
"        <strong>",
"         THEN",
"        </strong>",
"       </p>",
"       <p>",
"        Anticoagulation x4 more weeks",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"4\">",
"       Impaired cardiac function (EF &lt;40 percent or HF)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       (Does not apply)",
"      </td>",
"      <td>",
"       Note: If AF &gt;48 hours duration, use agents to convert rhythm with extreme caution in patients not receiving adequate anticoagulation because of possible embolic complications.",
"      </td>",
"      <td>",
"       <p>",
"        <strong>",
"         Consider:",
"        </strong>",
"       </p>",
"       <p>",
"        DC cardioversion",
"       </p>",
"       <p>",
"        <strong>",
"         OR",
"        </strong>",
"       </p>",
"       <p>",
"        Amiodarone (Class Ilb)",
"       </p>",
"       <p>",
"        <strong>",
"         Use only 1 of the following agents:",
"        </strong>",
"       </p>",
"       <p>",
"        Digoxin (Class lIb)",
"       </p>",
"       <p>",
"        Diltiazem (Class IIb)",
"       </p>",
"       <p>",
"        Amiodarone (Class Ilb)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Anticoagulation",
"       </p>",
"       <p>",
"        DC cardioversion",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: may have proarrhythmic potential. The classes listed represent the AHA Class of Recommendation and not the Vaughn-Williams classification of antiarrhythmics.",
"    <div class=\"footnotes\">",
"     WPW: Wolff-Parkinson-White syndrome; AF: atrial fibrillation; NSR: normal sinus rhythm; TEE: transesophageal echocardlogram; EF: ejection fraction.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: Circulation 2000 I-158.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_43_5821=[""].join("\n");
var outline_f5_43_5821=null;
var title_f5_43_5822="PACES HRS - Treatment asymptomatic pediatric WPW";
var content_f5_43_5822=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    PACES/HRS: Management of the asymptomatic young patient with Wolff-Parkinson-White syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 292px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Preexcitation is defined as premature activation of the ventricular myocardium by an anomalous pathway.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Patients unable to perform an exercise stress test should undergo risk stratification with an electrophysiology study.",
"     <br/>",
"     &Delta; Patients participating at moderate-high level competitive sports should be counseled with regards to risk-benefit of ablation and follow the 36th Bethesda Conference Guidelines.",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Cohen MI, Triedman JK, Cannon BC, et al. PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS). Heart Rhythm 2012; 9:1006. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_43_5822=[""].join("\n");
var outline_f5_43_5822=null;
var title_f5_43_5823="Atrophic morphea";
var content_f5_43_5823=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F70426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F70426&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atrophic morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 171px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severe atrophy is present in this patient with linear morphea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_43_5823=[""].join("\n");
var outline_f5_43_5823=null;
